U.S. patent application number 14/947107 was filed with the patent office on 2016-06-16 for cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures.
The applicant listed for this patent is Omeros Corporation. Invention is credited to Gregory A. Demopulos, Jeffrey M. Herz.
Application Number | 20160166555 14/947107 |
Document ID | / |
Family ID | 37452511 |
Filed Date | 2016-06-16 |
United States Patent
Application |
20160166555 |
Kind Code |
A1 |
Demopulos; Gregory A. ; et
al. |
June 16, 2016 |
Cyclooxygenase Inhibitor and Calcium Channel Antagonist
Compositions and Methods for Use in Urological Procedures
Abstract
Compositions of a cyclooxygenase inhibitor and a calcium channel
antagonist in a liquid carrier. The composition may be administered
the urinary tract during urological diagnostic, interventional,
surgical and other medical procedures. One disclosed composition
comprises ketoprofen and nifedipine in a liquid irrigation carrier,
and includes a solubilizing agent, stabilizing agents and a
buffering agent.
Inventors: |
Demopulos; Gregory A.;
(Mercer Island, WA) ; Herz; Jeffrey M.; (Mill
Creek, WA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Omeros Corporation |
Seattle |
WA |
US |
|
|
Family ID: |
37452511 |
Appl. No.: |
14/947107 |
Filed: |
November 20, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14199144 |
Mar 6, 2014 |
|
|
|
14947107 |
|
|
|
|
13454926 |
Apr 24, 2012 |
|
|
|
14199144 |
|
|
|
|
11378618 |
Mar 17, 2006 |
|
|
|
13454926 |
|
|
|
|
60683488 |
May 20, 2005 |
|
|
|
Current U.S.
Class: |
514/356 |
Current CPC
Class: |
A61L 2300/402 20130101;
A61P 29/00 20180101; A61P 13/02 20180101; A61K 31/00 20130101; A61L
31/16 20130101; A61P 13/00 20180101; A61P 13/06 20180101; A61K
9/0034 20130101; A61K 31/44 20130101; A61L 2300/432 20130101; A61K
31/4422 20130101; A61P 13/12 20180101; A61P 13/10 20180101; A61P
25/04 20180101; A61K 31/192 20130101; A61L 2300/41 20130101; A61K
31/4422 20130101; A61P 25/00 20180101; A61K 9/08 20130101; A61K
2300/00 20130101; A61K 2300/00 20130101; A61K 31/40 20130101; A61K
31/192 20130101; A61K 31/455 20130101; A61P 25/08 20180101; A61K
31/21 20130101 |
International
Class: |
A61K 31/4422 20060101
A61K031/4422; A61K 31/192 20060101 A61K031/192 |
Claims
1.-11. (canceled)
12. A method of inhibiting pain/inflammation and spasm in the
urinary tract, comprising: delivering to the urinary tract a
composition including a combination of ketoprofen and a calcium
channel antagonist in a carrier, each of the ketoprofen and the
calcium channel antagonist included in a therapeutically effective
amount such that the combination inhibits pain/inflammation and
spasm in the urinary tract.
13. The method of claim 12, wherein the composition is delivered
periprocedurally to the urinary tract during a urological
diagnostic, interventional, surgical and other medical
procedure.
14. The method of claim 13, wherein the composition is
periprocedurally delivered during a cystoscopic procedure.
15. The method of claim 13, wherein the composition is
periprocedurally delivered during a ureteroscopic procedure.
16. The method of claim 13, wherein the composition is
periprocedurally delivered during a procedure to remove, fragment
or dislodge a kidney or bladder stone.
17. The method of claim 13, wherein the composition is
periprocedurally delivered during a procedure that causes thermal
injury to urinary tract tissue.
18. The method of claim 17, wherein the composition is
periprocedurally delivered during a laser, microwave ablation,
radiofrequency ablation, electrocauterization or cryoblation
procedure.
19. The method of claim 13, wherein the composition is
periprocedurally delivered during a transurethral resection of a
prostate.
20. The method of claim 12, wherein the calcium channel antagonist
in the composition comprises nifedipine.
21. A method of inhibiting pain/inflammation and spasm in the
urinary tract during a diagnostic, interventional, surgical or
other medical urological procedure, comprising: periprocedurally
delivering to the urinary tract during a urological procedure a
composition including a combination of ketoprofen and nifedipine in
a carrier, each of the ketoprofen and the nifedipine included in a
therapeutically effective amount such that the combination inhibits
pain/inflammation and spasm in the urinary tract.
22. The method of claim 21, wherein the composition is during a
cystoscopic procedure.
23. The method of claim 21, wherein the composition is
periprocedurally delivered during a ureteroscopic procedure.
24. The method of claim 21, Wherein the composition is
periprocedurally delivered during a procedure to remove, fragment
or dislodge a kidney or bladder stone.
25. The method of claim 21, wherein the composition is
periprocedurally delivered during a procedure that causes thermal
injury to urinary tract tissue.
26. The method of claim 25, wherein the composition is
periprocedurally delivered during a laser, microwave ablation,
radiofrequency ablation, electrocauterization or cryoblation
procedure.
27. The method of claim 21, wherein the composition is
periprocedurally delivered during a transurethral resection of a
prostate.
28. The method of claim 21, wherein the composition is
periprocedurally delivered transrectally or transperitoneally to
the prostate.
29. A method of inhibiting pain/inflammation and spasm in the
urinary tract during a urological procedure, comprising:
periprocedurally delivering to the urinary tract during a
ureteroscopic procedure a composition including a combination of a
cyclooxygenase inhibitor and a calcium channel antagonist in a
carrier, each of the cyclooxygenase inhibitor and the calcium
channel antagonist included in a therapeutically effective amount
such that the combination inhibits pain/inflammation and spasm in
the urinary tract.
30. The method of claim 29, wherein the cyclooxygenase (COX)
inhibitor in the composition comprises a nonselective COX-1/COX-2
inhibitor.
31. A method of inhibiting pain/inflammation and spasm in the
urinary tract during a urological procedure, comprising:
periprocedurally delivering to the urinary tract during a procedure
to remove, fragment or dislodge a kidney or bladder stone a
composition including a combination of a cyclooxygenase inhibitor
and a calcium channel antagonist in a carrier, each of the
cyclooxygenase inhibitor and the calcium channel antagonist
included in a therapeutically effective amount such that the
combination inhibits pain/inflammation and spasm in the urinary
tract.
32. The method of claim 31, wherein the cyclooxygenase (COX)
inhibitor in the composition comprises a nonselective COX-1/COX-2
inhibitor.
33. A method of inhibiting pain/inflammation and spasm in the
urinary tract during a urological procedure, comprising:
periprocedurally delivering to the urinary tract during a procedure
that causes thermal injury to urinary tract tissue a composition
including a combination of a cyclooxygenase inhibitor and a calcium
channel antagonist in a carrier, each of the cyclooxygenase
inhibitor and the calcium channel antagonist included in a
therapeutically effective amount such that the combination inhibits
pain/inflammation and spasm in the urinary tract.
34. The method of claim 33, wherein the cyclooxygenase (COX)
inhibitor in the composition comprises a nonselective COX-1/COX-2
inhibitor.
35. The method of claim 34, wherein the composition is delivered
periprocedurally to the urologic structure during a laser,
microwave ablation, radiofrequency ablation, electrocauterization
or cryoblation procedure.
36. A method of inhibiting pain/inflammation and spasm during a
urological procedure, comprising: periprocedurally delivering
transrectally or transperitoneally to the prostate a composition
including a combination of a cyclooxygenase inhibitor and a calcium
channel antagonist in a carrier, each of the cyclooxygenase
inhibitor and the calcium channel antagonist included in a
therapeutically effective amount such that the combination inhibits
pain/inflammation and spasm.
37. The method of claim 36, wherein the cyclooxygenase (COX)
inhibitor in the composition comprises a nonselective COX-1/COX-2
inhibitor.
38. A method of inhibiting pain, inflammation and/or spasm in the
urinary tract during a urological procedure, comprising:
periprocedurally delivering to the urinary tract during a
ureteroscopic procedure a composition including a combination of a
plurality of agents that inhibit pain/inflammation and/or spasm in
a carrier, each agent included in a therapeutically effective
amount such that the combination inhibits pain/inflammation and/or
spasm in the urinary tract.
39. A method of inhibiting pain, inflammation and/or spasm in the
urinary tract during a urological procedure, comprising:
periprocedurally delivering to the urinary tract during a procedure
to remove, fragment or dislodge a kidney or bladder stone a
composition including a combination of a plurality of agents that
inhibit pain/inflammation and/or spasm in a carrier, each agent
included in a therapeutically effective amount such that the
combination inhibits pain/inflammation and/or spasm in the urinary
tract.
40. A method of inhibiting pain, inflammation and/or spasm in the
urinary tract during a urological procedure, comprising:
periprocedurally delivering to the urinary tract during a procedure
that causes thermal injury to urinary tract tissue a composition
including a combination of a plurality of agents that inhibit
pain/inflammation and/or spasm in a carrier, each agent included in
a therapeutically effective amount such that the combination
inhibits pain/inflammation and/or spasm in the urinary tract.
41. The method of claim 40, wherein the composition is delivered
periprocedurally to the urologic structure during a laser,
microwave ablation, radiofrequency ablation, electrocauterization
or cryoblation procedure.
42. A method of inhibiting pain, inflammation and/or spasm during a
urological procedure, comprising: periprocedurally delivering
transrectally or transperitoneally to the prostate a composition
including a combination of a plurality of agents that inhibit
pain/inflammation and/or spasm in a carrier, each agent included in
a therapeutically effective amount such that the combination
inhibits pain/inflammation and/or spasm.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation of U.S. patent
application Ser. No. 14/199,144 filed Mar. 6, 2014, which is a
continuation of U.S. patent application Ser. No. 13/454,926, filed
Apr. 24, 2012, now abandoned, which is a continuation of U.S.
patent application Ser. No. 11/378,618, filed Mar. 17, 2006, now
abandoned, which application claims the benefit of U.S. Provisional
Application No. 60/683,488, filed May 20, 2005.
FIELD OF THE INVENTION
[0002] The present invention relates to pharmaceutical compositions
for administration to the urinary tract during urological
diagnostic, interventional, surgical and other medical procedures
and for therapeutic treatment of urologic structures.
BACKGROUND OF THE INVENTION
[0003] Many urological procedures are now performed using minimally
invasive endoscopic (e.g., cystoscopic or uteroscopic) techniques.
These include examination of the urethra, bladder and ureters,
therapeutic treatments for benign prostatic hypertrophy, removal or
fragmentation of kidney and bladder stones, the placement of
urethral or ureteral stents to facilitate the passage of stones,
the performance of biopsies and the excision of tumors. While less
invasive than open surgery, these techniques involve procedural
irritation and trauma to the urinary tract leading to pain,
inflammation and smooth muscle spasm. Postoperative lower urinary
tract symptoms (LUTS) following urological procedures often include
pain, hyperreflexia (unstable bladder contractions), urinary
frequency, nocturia and urgency, and in some cases urinary
retention requiring prolonged catheterization.
[0004] For some surgical procedures, such as transurethral
resection of the prostate (TURP), frequent urination and other
symptoms resulting from the procedural irritation and inflammation
may continue for a prolonged period, gradually resolving during the
first six postoperative weeks. For urologic procedures employing a
laser, postoperative complications such as inflammation and muscle
spasm may continue for several weeks. Patients are frequently
prescribed oral anticholinergic medication to inhibit postoperative
spasm and reduce the severity of unstable contractions. However,
not all patients respond adequately to these drugs, and side
effects may lead to discontinuation of these medications.
[0005] Urological procedures are often performed with concurrent
irrigation of the urinary tract, to remove blood and tissue debris
so that a clear endoscopic field of view is maintained.
Conventional irrigation solutions include saline, lactated
Ringer's, glycine, sorbitol, manitol and sorbitol/manitol. These
conventional irrigation solutions do not contain active
pharmaceutical agents.
[0006] U.S. Pat. No. 5,858,017 to Demopulos, et al., the disclosure
of which is hereby incorporated by reference, discloses surgical
irrigation solutions and methods for the inhibition of pain,
inflammation and/or spasm. The use of irrigation solutions
containing pain/inflamation inhibitors and anti-spasm agents during
urological procedures in general and during TURP specifically is
disclosed, including five-drug and nine-drug combinations. This
reference does not teach optimized pairings of a pain/inflammation
inhibitory agent with an anti-spasm agent for given urological
procedures.
SUMMARY OF THE INVENTION
[0007] The present invention provides a locally deliverable
composition for inhibiting pain/inflammation and spasm, comprising
a combination of ketoprofen and a calcium channel antagonist in a
carrier. Ketoprofen and the calcium channel antagonist are each
included in a therapeutically effective amount such that the
combination inhibits pain/inflammation and spasm at a site of local
delivery.
[0008] In a further aspect of the present invention, a locally
deliverable composition for inhibiting pain/inflammation and spasm
comprises a combination of a cyclooxygenase inhibitor and a calcium
channel antagonist, propyl gallate as a stabilizing agent and a
liquid carrier. Each active agent is included in a therapeutically
effective amount such that the combination inhibits
pain/inflammation and spasm at a site of local delivery.
[0009] In a further aspect of the present invention, a locally
deliverable composition for inhibiting pain/inflammation and spasm
comprises a combination of a cyclooxygenase inhibitor and a calcium
channel antagonist an aqueous liquid carrier, a cosolvent, at least
one stabilizing agent and a buffer. Each active agent is included
in a therapeutically effective amount such that the combination
inhibits pain/inflammation and spasm at a site of local
delivery.
[0010] A further aspect of the present invention provides a method
of inhibiting pain/inflammation and spasm in the urinary tract,
comprising delivering to the urinary tract a composition including
a combination of ketoprofen and a calcium channel antagonist in a
carrier. Ketoprofen and the calcium channel antagonist are each
included in a therapeutically effective amount such that the
combination inhibits pain/inflammation and spasm in the urinary
tract.
[0011] A still further aspect of the present invention provides a
method of inhibiting pain/inflammation and spasm in the urinary
tract during a diagnostic, interventional, surgical or other
medical urological procedure, comprising periprocedurally
delivering to the urinary tract during a urological procedure a
composition including a combination of ketoprofen and nifedipine in
a carrier. Ketoprofen and nifedipine are each included in a
therapeutically effective amount such that the combination inhibits
pain/inflammation and spasm in the urinary tract.
[0012] A still further aspect of the present invention provides a
method of inhibiting pain/inflammation and spasm in the urinary
tract during a urological procedure, comprising periprocedurally
delivering to the urinary tract during a ureteroscopic procedure a
composition including a combination of a cyclooxygenase inhibitor
and a calcium channel antagonist in a carrier. The cyclooxygenase
inhibitor and the calcium channel antagonist are each included in a
therapeutically effective amount such that the combination inhibits
pain/inflammation and spasm in the urinary tract.
[0013] A still further aspect of the present invention provides a
method of inhibiting pain/inflammation and spasm in the urinary
tract during a urological procedure, comprising periprocedurally
delivering to the urinary tract during a procedure to remove,
fragment or dislodge a kidney or bladder stone a composition
including a combination of a cyclooxygenase inhibitor and a calcium
channel antagonist in a carrier. The cyclooxygenase inhibitor and
the calcium channel antagonist are each included in a
therapeutically effective amount such that the combination inhibits
pain/inflammation and spasm in the urinary tract.
[0014] A still further aspect of the present invention provides a
method of inhibiting pain/inflammation and spasm in the urinary
tract during a urological procedure, comprising periprocedurally
delivering to a urologic structure during a procedure that causes
thermal injury to urinary tract tissue a composition including a
combination of a cyclooxygenase inhibitor and a calcium channel
antagonist in a carrier. The cyclooxygenase inhibitor and the
calcium channel antagonist are each included in a therapeutically
effective amount such that the combination inhibits
pain/inflammation and spasm in the urinary tract.
[0015] A still further aspect of the present invention provides a
method of inhibiting pain, inflammation and/or spasm in the urinary
tract during a urological procedure, comprising periprocedurally
delivering to a urologic structure during a ureteroscopic procedure
a composition including a combination of a plurality of agents that
inhibit pain/inflammation and/or spasm in a carrier. Each agent is
included in a therapeutically effective amount such that the
combination inhibits pain/inflammation and/or spasm in the urinary
tract.
[0016] A still further aspect of the present invention provides a
method of inhibiting pain, inflammation and/or spasm in the urinary
tract during a urological procedure, comprising periprocedurally
delivering to a urologic structure during a procedure to remove,
fragment or dislodge a kidney or bladder stone a composition
including a combination of a plurality of agents that inhibit
pain/inflammation and/or spasm in a carrier. Each agent is included
in a therapeutically effective amount such that the combination
inhibits pain/inflammation and/or spasm in the urinary tract.
[0017] A still further aspect of the present invention provides a
method of inhibiting pain, inflammation and/or spasm in the urinary
tract during a urological procedure, comprising periprocedurally
delivering to a urologic structure during a procedure that causes
thermal injury to urinary tract tissue a composition including a
combination of a plurality of agents that inhibit pain/inflammation
and/or spasm in a carrier. Each agent is included in a
therapeutically effective amount such that the combination inhibits
pain/inflammation and/or spasm in the urinary tract.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The present invention will now be described in greater
detail, by way of example, with reference to the accompanying
drawings in which:
[0019] FIG. 1 provides a model for action of prostaglandin
activity.
[0020] FIG. 2 illustrates the bradykinin and substance P cumulative
concentration-response curves obtained from normal animals in
Example I.
[0021] FIG. 3A illustrates bradykinin concentration-response curves
produced in the presence of 0.25, 1.0, 2.5 and 10 .mu.M ketoprofen
from Example I; FIG. 3B illustrates the Schild plot for pA2
analysis of ketoprofen from Example I.
[0022] FIG. 4A demonstrates that bradykinin rapidly induces the
formation of PGE.sub.2 in rat bladder tissue strips tested in
Example I within the first minutes of stimulation and reaches a
maximum within 30 minutes, with a t.sub.1/2 for formation of about
7.5 minutes. FIG. 4B illustrates the rapid kinetics of PGE.sub.2
formation detected within minutes in Example I.
[0023] FIG. 5A illustrates that intravenous aspirin (10 mg/kg)
produced a gradual time-dependent inhibition of the acetic acid
induced reduction in the intercontraction interval (ICI), and FIG.
5B illustrates the parallel changes in bladder capacity, from
Example I.
[0024] FIG. 6 shows the effect of increasing concentrations of
nifedipine on contractility of rat bladder strips from Example
II.
[0025] FIG. 7 shows the combined effect of nifedipine (0.1 .mu.M)
and ketoprofen (0.3-3.0 .mu.M) on bradykinin-stimulated
contractility of rat bladder strips from Example III.
[0026] FIG. 8 shows the combined effect of nifedipine (0.3 .mu.M)
and ketoprofen (0.3-3.0 .mu.M) on bradykinin-stimulated
contractility of rat bladder strips from Example III.
[0027] FIG. 9 shows the combined effect of nifedipine (1.0 .mu.M)
and ketoprofen (0.3-3.0 .mu.M) on bradykinin-stimulated
contractility of rat bladder strips from Example III.
[0028] FIG. 10 illustrates the concentration-response surface
(reduced model) of individual tension values from dose response
curves corresponding to 30 .mu.M bradykinin-induced tension in rat
bladder strips from Example III.
[0029] FIG. 11 shows the effect of ketoprofen (10 .mu.M) and
nifedipine (1 .mu.M), individually, on multiple agonist-stimulated
tension in rat bladder tissue strips from Example IV.
[0030] FIG. 12 shows the effect of ketoprofen (10 .mu.M) and
nifedipine (1 .mu.M), individually, on bradykinin-stimulated
PGE.sub.2 release from rat bladder tissue strips from Example
IV.
[0031] FIG. 13 shows a rat bladder cystometry tracing demonstrating
the effect of acetic acid perfused as described in Example V.
[0032] FIG. 14 demonstrates the effect of ketoprofen pretreatment
on acetic acid-induced bladder hyperactivity from Example V.
[0033] FIG. 15 demonstrates the effect of nifedipine pretreatment
on acetic acid-induced bladder hyperactivity from Example V.
[0034] FIG. 16 illustrates mean ketoprofen plasma levels for rats
treated with ketoprofen or a combination of ketoprofen and
nifedipine in the pharmacokinetic study of Example VI.
[0035] FIG. 17 illustrates mean nifedipine plasma levels for rats
treated with nifedipine or a combination of ketoprofen and
nifedipine in the pharmacokinetic study of Example VI.
[0036] FIG. 18 illustrates the effects of nifedipine, ketoprofen
and a combination of nifedipine and ketoprofen on PGE.sub.2 in rat
bladders from the pharmacokinetic study of Example VI.
[0037] FIG. 19 shows a chromatogram of a nifedipine and ketoprofen
formulation F1 in accordance with Example VIII after having been
stressed at 60.degree. C. for 1 month.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0038] The present invention provides methods and compositions for
inhibiting pain, inflammation and/or spasm during urological
procedures by locally delivering such compositions to structures of
the urological tract during the procedure. The compositions include
at least one agent that is a pain/inflammation inhibitory agent or
a spasm inhibitory agent, or that acts to inhibit both
pain/inflammation and spasm. Preferably, the compositions and
methods of the present invention include two or more
pain/inflammation inhibitory or spasm inhibitory agents that act on
different molecular targets (i.e., enzymes, receptors or ion
channels) or that act through different mechanisms of action. More
preferably, the compositions of the present invention include at
least one pain/inflammation inhibitory agent and at least one spasm
inhibitory agent.
[0039] As used herein, the term "pain/inflammation inhibitory
agent" includes analgesic agents (i.e., antinociceptive agents),
non-steroidal agents that inhibit inflammation [including both
"non-steroidal anti-inflammatory drugs" (i.e., NSAIDS or
cyclooxygenase inhibitors) and other agents that are not steroidal
that act to inhibit inflammation], corticosteroids and local
anesthetics.
[0040] As used herein, the term "spasm inhibitory agent" includes
agents that inhibit spasm or contraction of smooth muscle tissue
and agents that inhibit spasm or contraction of other muscle tissue
associated with the urinary tract (e.g., prostatic muscle
tissue).
[0041] Another aspect of the present invention is directed to the
periprocedural delivery to the urinary tract of a cyclooxygenase
(COX) inhibitor, suitably a non-selective COX-1/COX-2 inhibitor,
preferably a non-selective COX-1/COX-2 inhibitor that is a
propionic acid derivative, more preferably ketoprofen, alone or
with at least one additional agent that inhibits pain/inflammation
and/or that inhibits spasm, such as a calcium channel
antagonist.
[0042] Another aspect of the present invention is directed to the
periprocedural delivery to the urinary tract of a calcium channel
antagonist (i.e., a calcium channel blocker), suitably an L-type
calcium antagonist, preferably a dihydropyridine calcium channel
antagonist, more preferably nifedipine, alone or with at least one
additional agent that inhibits pain/inflammation and/or that
inhibits spasm, such as a COX inhibitor.
[0043] Another aspect of the present invention is directed to the
periprocedural delivery to the urinary tract of a combination of a
COX inhibitor and a calcium channel antagonist, preferably a
non-selective COX-1/COX-2 inhibitor in combination with an L-type
calcium antagonist, more preferably ketoprofen in combination with
nifedipine. Ketoprofen and nifedipine have been found by the
present inventors to provide greater than additive or synergistic
results in the inhibition of bladder spasm, as described in the
examples below.
[0044] One aspect of the present invention entails the local
delivery of the compositions of the present invention to the
bladder, ureter, urethra, or other urinary tract structures to
inhibit pain, inflammation and/or smooth muscle spasm during
urological therapeutic, diagnostic, interventional, surgical and
other medical procedures.
[0045] As used herein, the terms "urinary tract" and "urinary
sytem" refer to the kidneys, ureters, bladder, urethra and
associated nerves, blood vessels and muscles. The term "lower
urinary tract" refers to the bladder and urethra and associated
nerves, blood vessels and muscles.
[0046] A further aspect of the present invention entails the local
delivery of the compositions of the present invention to urinary
tract structures to reduce postoperative irritative voiding
symptoms (e.g., void frequency, nocturia, urgency), pain and/or
other lower urinary tract symptoms following such urological
procedures.
[0047] A further aspect of the present invention entails the local
delivery of the compositions of the present invention to urinary
tract structures to improve postoperative urinary function (e.g.,
decrease undesirable urinary retention) following such urological
procedures.
[0048] The compositions of the present invention are suitably
delivered to the urinary tract before, during and/or after
urological procedures, i.e., before (pre-) procedurally, during
(intra-) procedurally, after (post-) procedurally, pre- and
intraprocedurally, pre- and postprocedurally, intra- and
postprocedurally or pre-, intra- and postprocedurally.
[0049] Preferably, the compositions of the present invention are
locally delivered to the urinary tract "periprocedurally", which as
used herein means intraprocedurally, pre- and intraprocedurally,
intra- and postprocedurally or pre-, intra- and postprocedurally.
Periprocedural delivery may be either continuous or intermittent
during the procedure. Preferably, the compositions of the present
invention are delivered "continuously" during the procedure, which
as used herein means delivery so as to maintain an approximately
constant concentration of active agent(s) at the local delivery
site. When delivered periprocedurally during a surgical procedure,
the term "perioperatively" may be used interchangeably with
periprocedurally herein. Preferably, the compositions of the
present invention are delivered periprocedurely during the period
of time when surgical or other procedural trauma and irritation is
being incurred by urinary tract tissue.
[0050] "Local" delivery of the compositions of the present
invention to the urinary tract as used herein refers to delivery of
the compositions directly to one or more structures of the urinary
tract. The therapeutic agent(s) contained in the locally delivered
compositions are not subject to first and/or second pass metabolism
before reaching the local site of intended therapeutic (e.g.,
inhibitory) effect, in contrast to systemically delivered
drugs.
Pathophysiologic Effects of Urological Procedures
[0051] The trauma of urological procedures results in an acute,
localized inflammatory response in the associated urological
structures. Inflammation is associated with a complex pattern of
biochemical and cellular processes occurring at the local site,
involving positive-feedback interactions between the peripheral
nervous system, immune cells, the local vasculature and the central
nervous system. The inflammatory response to procedural trauma in
the urinary tract includes cytokine release, inflammatory cell
migration, edema, pain and hyperalgesia.
[0052] In response to tissue injury, numerous local mediators are
rapidly released, which result in nociceptive stimulation of
sensory C-fibers. The inflammatory response triggered by peripheral
injury shows that, in addition to cytokines, small G-protein
receptor-linked inflammatory mediators also modulate the rapid
pathophysiological response of the bladder and urethra. In models
of urinary bladder inflammation, bradykinin, histamine, substance P
(SP), leukotrienes and prostaglandins have been found to be
released from the bladder. Lecci, A., et al., Pharmacological
Analysis of the Local and Reflex Responses to Bradykinin on Rat
Urinary Bladder Motility in Vivo, Br. J. Pharmacol., 114:708-14
(1995); Lecci, A., et al., Capsaicin Pretreatment Does Not Alter
Rat Urinary Bladder Motor Responses Induced by a Kinin B1 Receptor
Agonist After Endotoxin Treatment, Neurosci. Lett. 262:73-76
(1999); Vasko, M., et al., Prostaglandin E2 Enhances
Bradykinin-Stimulated Release of Neuropeptides from Rat Sensory
Neurons in Culture, J Neurosci. 14:4987-97 (1994). Certain
inflammatory mediators, such as prostaglandins and kinins, activate
and sensitize C-fibers through interaction with specific receptors
on nerve terminals. Other inflammatory mediators that have been
described in the lower urinary tract include tachykinins and ATP
(from C-fibers) (Maggi, C., et al., Tachkykinin Antagonists and
Capsaicin-Induced Contraction of the Rat Isolated Urinay Bladder:
Evidence for Tachykinin-Mediated Cotransmission, Br. J. Pharmacol.
103:1535-41 (1991), CGRP (from C-fibers), serotonin (from mast
cells and platelets), and endothelin. Maggi, C., et al.,
Contractile Responses of the Human Urinary Bladder, Renal Pelvis
and Renal Artery to Endothelins and Sarafotoxin S6b, Gen.
Pharmacol. 21:247-49 (1990). These mediators operate together in a
synergistic manner to increase postsurgical hyperalgesia,
inflammation and muscle spasm. The number of mediators involved in
the response underscores the multifactorial origin of the pain and
inflammation process.
[0053] The immediate activation of the sensory nerves (primary
hyperalgesia) triggers a cascade of processes that involves
alterations in the local vasculature, and influences muscle
contractility. Capsaicin-sensitive afferent fiber stimulation
elicits a local efferent response, which is characterized by
release of neuropeptides (tachykinins and CGRP) from nerve endings.
This release produces a number of local responses, which are part
of the pathophysiological effects in the lower urinary tract. These
include: (1) direct effects of released neurotransmitters on smooth
muscle contraction; (2) changes in microvascular permeability
resulting in plasma extravasation and edema of the bladder, urethra
and prostate; (3) infiltration of immune cells; and (4)
sensitization of nociceptors (secondary hyperalgesia) resulting in
increased pain. The consequences of these processes can affect
normal bladder capacity and frequency of micturition, and often
result in hypersensitivity, pain and smooth muscle spasm.
[0054] The pathophysiologic response to procedural trauma of the
urinary tract involves a complex cascade of molecular signaling and
biochemical changes resulting in inflammation, pain, spasm and
lower urinary tract symptoms. These are preferably addressed in
accordance with the methods and compositions of the present
invention by locally and periprocedurally delivering a combination
of pharmacologic agents acting on multiple molecular targets to
inhibit pain, inflammation and/or spasm. Preferred agents include
cyclooxygenase inhibitors and calcium channel antagonists, more
preferably in combination.
Cyclooxygenase Inhibitors
[0055] Prostaglandins are produced throughout the lower urinary
tract and play a role in neurotransmission, bladder contractility
and inflammatory responses. Human bladder mucosa has been found to
contain several types of prostaglandins, which have been shown to
contract the human detrusor. Prostaglandin E.sub.2 (PGE.sub.2) is a
potent mediator of pain and edema, and the exogenous administration
of PGE.sub.2 induces contractile responses in inflamed bladders.
Intravesical PGE.sub.2 produces both urgency and involuntary
bladder contractions. Lepor, H., The Pathophysiology of Lower
Urinary Tract Symptoms in the Ageing Male Population, Br. J Urol.,
81 Suppl 1:29-33 (1998); Maggi, C., et al., Prostanoids Modulate
Reflex Micturition by Acting Through Capsaicin-Sensitive Afferents,
Eur. J. Pharmacol. 145: 105-12 (1988). PGE.sub.2 given
intravesically may stimulate micturition by releasing tachykinins
from nerves in and/or immediately below the urothelium. Ishizuka,
O., et al., Prostaglandin E2-Induced Bladder Hyperactivity in
Normal, Conscious Rats: Involvement of Tachykinins?, J Urol.
153:2034-38 (1995). Prostanoids may, via release of tachykinins,
contribute to both urge and bladder hyperactivity seen in
inflammatory conditions of the lower urinary tract. While not
wishing to be limited by theory, these actions are most likely
mediated through activation of specific prostanoid receptor
subtypes (EP1R) located on C-fibers and on bladder smooth muscle
(FIG. 1).
[0056] In the inflamed bladder, the basal production of PGE.sub.2
is significantly higher than in control conditions. A number of
inflammatory mediators acting through GPCR pathways that are linked
to the production of arachidonic acid may up-regulate prostaglandin
levels in the mucosa and vascular endothelium. Bradykinin is a
well-established mediator of inflammation, and bradykinin receptor
agonists stimulate greater PGE.sub.2 production in inflamed
bladders than in control bladders. Topical application of
bradykinin activates bladder sensory nerves. Lecci, A., et al.,
Kinin B1 Receptor-Mediated Motor Responses in Normal or Inflamed
Rat Urinary Bladder in Vivo, Regul. Pept. 80:41-47 (1999); Maggi,
C., et al., Multiple Mechanisms in the Motor Responses of the
Guinea-Pig Isolated Urinary Bladder to Bradykinin, Br. J.
Pharmacol. 98:619-29 (1989). Contractile responses elicited by the
selective B1 and B2 receptor agonists tested in isolated rat
urinary bladder strips showed that the contractile responses to a
selective B1 agonist were also potentiated in inflamed bladders.
The role of bradykinin in reflex voiding has also been investigated
in normal rats using continuous infusion cystometry. Infusion of
bradykinin produced a significant decrease in the intercontraction
interval (ICI) between voiding events and an increase in bladder
contraction amplitude that is completely blocked by a B2 receptor
antagonist.
[0057] Microvascular leakage induced by administration of substance
P acting through the NK1 receptor also involves the release of
cyclooxygenase metabolites of arachidonic acid. Abelli, L., et al.,
Microvascular Leakage Induced by Substance P in Rat Urinary
Bladder: Involvement of Cyclo-oxygenase Metabolites of Arachidonic
Acid, J. Auton. Pharmacol. 12:269-76 (1992). These findings
demonstrate that distinct inflammatory mediators act through
independent receptor mechanisms to trigger the production of
prostaglandins. NSAIDs that act at a common target downstream of
multiple GPCRs to inhibit COX-1/COX-2 have the capacity to block
the formation of prostaglandins derived from multiple
proinflammatory mediators.
[0058] A number of studies have shown that both COX-1 and COX-2 are
involved in the production of PGE.sub.2 during tissue trauma and
the acute inflammatory response. Martinez, R., et al., Involvement
of Peripheral Cyclooxygenase-1 and Cyclooxygenase-2 in Inflammatory
Pain, J Pharm Pharmacol. 54:405-412 (2002); Mazario, J, et al.,
Cyclooxygenase-1 vs. Cyclooxygenase-2 Inhibitors in the Induction
of Antinociception in Rodent Withdrawal Reflexes,
Neuropharmacology. 40:937-946 (2001); Torres-Lopez, J., et al.,
Comparison of the Antinociceptive Effect of Celecoxib, Diclofenac
and Resveratrol in the Formalin Test, Life Sci. 70:1669-1676
(2002). In normal bladders, activation of B2 receptors evokes
bladder contraction mediated by COX-1 activity, whereas COX-2
activity is involved in production of PGE.sub.2 driven through
stimulation of B1 receptors only. COX-2 is the major isoform that
is rapidly expressed and dramatically up-regulated during bladder
inflammation. It is believed to be responsible for the high levels
of prostanoids released during acute and chronic inflammation of
the bladder. COX-2 is up-regulated in response to proinflammatory
cytokines and bladder treatment with either endotoxin or
cyclophosphamide. Both COX isozymes are therefore suitable
molecular targets for the drug compositions of the present
invention.
[0059] An aspect of the present invention is directed to
therapeutic compositions including a cyclooxygenase inhibitor in a
carrier suitable for local delivery to urologic structures in the
urinary tract. To achieve maximal inhibition of prostaglandin
synthesis at sites of acute inflammation, it is believed desirable
to inhibit both COX isoenzymes.
[0060] The COX inhibitor is therefore preferably non-selective with
respect to activity at COX-1 and COX-2, which for purposes of the
present invention may be defined as an agent for which the ratio of
(a) the concentration of the agent effective for the inhibition of
50% (IC50) of the activity of COX-1 relative to (b) the IC50 for
the inhibition of the activity of COX-2 is greater than or equal to
0.1 and less than or equal to 10.0, and more preferably is greater
than or equal to 0.1 and less than or equal to 1.0. Suitable assays
for determining COX-1 and COX-2 inhibitory effect are disclosed in
Riendau, D., et al., Comparison of the Cyclooxygenase-1 Inhibitory
Properties of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and
Selective COX-2 Inhibitors, Using Sensitive Microsomal and Platelet
Assays, Can. J. Physiol. Pharmacol. 75:1088-1095 (1997).
[0061] Suitable non-selective COX-1/COX-2 inhibitors include, for
purposes of illustration, salicylic acid derivatives including
aspirin, sodium salicylate, choline magnesium trisalicylate,
salsalate, diflunisal, sulfasalazine and olsalazine,
para-aminophenol derivatives such as acetaminophen, indole and
indene acetic acids such as indomethacin and sulindac, heteroaryl
acetic acids including tolmetin, diclofenac and keterolac,
arylpropionic acids including ibuprofen, naproxen, flurbiprofen,
ketoprofen, fenoprofen and oxaprozin, anthranilic acids (fenamates)
including mefanamic acid and meclofenamic acid, enolic acids
including oxicams such as piroxicam and meloxicam and alkanones
such as nabumetone, as well as pharmaceutically effective esters,
salts, isomers, conjugates and prodrugs thereof.
[0062] Still more preferably, the non-selective COX-1/COX-2
inhibitor is an arylpropionic acid, i.e., a propionic acid
derivative, such as ketoprofen, dexketoprofen, ibuprofen, naproxen,
flurbiprofen, fenoprofen and oxaprozin. Most preferably, the agent
is ketoprofen.
[0063] In another aspect of the invention, the non-selective
COX-1/COX-2 inhibitor used in the compositions and methods of the
present invention is selected as having an IC50 for the inhibition
of bradykinin-induced bladder smooth-muscle strip contractility (as
determined by the bladder contractility model described herein
below) of less than or equal to 100 .mu.M, preferably less than or
equal to 25 .mu.M, more preferably less than or equal to 5 .mu.M,
still more preferably less than 2 .mu.M.
[0064] In a further aspect of the invention, the non-selective
COX-1/COX-2 inhibitor used in the compositions and methods of the
present invention is selected as having an IC50 for the inhibition
of bradykinin-induced prostaglandin E.sub.2 (PGE.sub.2) (as
determined by the PGE.sub.2 bladder tissue analysis model described
herein below) of less than or equal to 100 .mu.M, preferably less
than or equal to 25 .mu.M, more preferably less than or equal to 5
.mu.M, still more preferably less than 2 .mu.M.
[0065] In a still further aspect of the invention, the
non-selective COX-1/COX-2 inhibitor used in the compositions and
methods of the present invention is selected as having (a) an IC50
for the inhibition of bradykinin-induced bladder smooth-muscle
strip contractility (as determined by the bladder contractility
model described herein below) of less than or equal to 100 .mu.M,
preferably less than or equal to 25 .mu.M, more preferably less
than or equal to 5 .mu.M, still more preferably less than 2 .mu.M,
and (b) an IC50 for the inhibition of bradykinin-induced PGE.sub.2
(as determined by the PGE.sub.2 bladder tissue analysis model
described herein below) of less than or equal to 100 .mu.M,
preferably less than or equal to 25 .mu.M, more preferably less
that or equal to 5 .mu.M, still more preferably less than 2
.mu.M.
[0066] The above noted IC50 concentrations are not to be
interpreted as limitations on drug concentrations in the
compositions of the present invention, which may suitably be
determined by the concentrations needed to approach maximal
effectiveness and thus may be higher than the IC50 levels.
[0067] In a still further aspect of the invention, the
non-selective COX-1/COX-2 inhibitor used in the compositions and
methods of the present invention is selected as having a pA.sub.2
(antagonist potency) of greater than or equal to 7, wherein
pA.sub.2 is the negative logarithm of the concentration of
antagonist that would produce a 2-fold shift in the concentration
response curve for an agonist, and is a logarithmic measure of the
potency of an antagonist. This potency corresponds to an
equilibrium dissociation constant K.sub.D of less than or equal to
100 nM.
[0068] In a still further aspect of the invention, the
non-selective COX-1/COX-2 inhibitor used in the compositions and
methods of the present invention exhibits 50% of maximal inhibitory
response in less than or equal to 10 minutes in a kinetic study of
bradykinin-stimulated PGE.sub.2 response in the PGE.sub.2 bladder
tissue analysis model described herein below.
Ketoprofen
[0069] Unless used in a context also referring to its isomer,
references herein to the use of ketoprofen (i.e.,
m-benzoylhydratropic acid or 3-benzoyl-.alpha.-methylbenzeneacetic
acid) in the present invention are to be understood to also include
pharmaceutically acceptable isomers thereof, including its racemic
S-(+)-enantiomer, dexketoprofen, pharmaceutically acceptable salts
or esters thereof, and pharmaceutically acceptable prodrugs or
conjugates thereof. Ketoprofen is a preferred COX inhibitor for use
in the present invention.
[0070] Ketoprofen exhibits potent anti-inflammatory, analgesic, and
antipyretic actions that are associated with the inhibition of
prostaglandin synthesis and antagonism of the effects of
bradykinin. Ketoprofen non-selectively inhibits the activity of
COX-1 and COX-2, which results in the blockade of prostaglandin
production, particularly that of PGE.sub.2, preventing the
development of hyperalgesia. Ketoprofen has an IC.sub.50 value of
4-8 nM in a non-selective COX assay, being functionally 6-12 times
more potent than other NSAIDs evaluated (e.g., naproxen or
indomethacin). Kantor, T., Ketoprofen: A review of its
Pharmacologic and Clinical Properties, Pharmacotherapy 6:93-103
(1986). Ketoprofen also has functional bradykinin antagonist
activity, its effects being eight times greater than those seen
with the classical NSAID, indomethacin. Julou, L., et al.,
Ketoprofen (19.583 R.P.) (2-(3-Benzoylphenyl)-propionic acid). Main
Pharmacological Properties--Outline of Toxicological and
Pharmacokinetic Data, Scand J Rheumatol Suppl. 0:33-44 (1976).
[0071] In addition to inhibiting cyclooxygenase, ketoprofen is
believed to offer the additional anti-inflammatory benefit of
inhibiting lipoxygenase. Ketoprofen has also been found to
synergise with nifedipine in the inhibition of bladder spasm, as
discussed in greater detail in the examples below.
Calcium Channel Antagonists
[0072] Multiple inflammatory mediators, including bradykinin, are
released into the bladder in response to tissue injury, which can
trigger smooth muscle contraction and spasm. The tone of the
urinary bladder smooth muscle is regulated by numerous
contraction-promoting receptor systems. They include well
established systems such as muscarinic, purinergic and tachykinin
receptors [Anderson, K., et al., Pharmacolgy of the Lower Urinary
Tract: Basis for Current and Future Treatments for Urinary
Incontenance Pharmacol Rev. 56:581-631 (2004)], and also include
endothelin receptors [Afiatpour, P., et al., Development Changes in
the Functional, Biochemical and Molecular Properties of Rat Bladder
Endothelin Receptors, Naunyn Schmiedebergs Arch. Pharmacol.
367:462-72 (2003)], protease-activated receptors and bradykinin
receptors [Kubota, Y., et al., Role of Mitochondria in the
Generation of Spontaneous Activity in Detrusor Smooth Muscles of
the Guinea Pig Bladder, J. Urol. 170:628-33 (2003); Trevisani, M.,
et al., Evidence for In Vitro Expression of B1 Receptor in the
Mouse Trachea and Urinary Bladder, Br. J. Pharmacol. 126:1293-1300
(1999)]. Because many of these receptors are prototypically coupled
via G.sub.q proteins to the activation of a phospholipase C (PLC),
it is likely that bladder contraction elicited by such receptors is
partly mediated by PLC-linked mobilization of Ca.sup.2+ from
intracellular stores [Ouslander, J. G., Management of Overactive
Bladder, N. Engl. J. Med., 350:786-99 (2004)].
[0073] Neurally mediated contractions of the bladder and urethral
smooth muscle require mobilization of intracellular Ca.sup.2+ as
well as an influx of extracellular Ca.sup.2+. Ca.sup.2+ entry
through L-type calcium channels can contribute to muscle
contractions by triggering the intracellular release of Ca.sup.2+,
which opens ryanodine-sensitive Ca.sup.2+ release channels in the
sarcoplasmic reticulum. Opening of L-type calcium channels in
bladder muscle also serves to replace intracellular Ca.sup.2+
stores after contraction. Recent studies conclude that muscarinic
receptor subtype signaling mediated via carbachol-induced
contraction of rat bladders largely depends on Ca.sup.2+ entry
through L-type calcium channels and, perhaps, PLD, PLA.sub.2 and
store-operated Ca.sup.2+ channels. Schneider, T., et al., Signal
Transduction Underlying Carbachol-Induced Contraction of Rat
Urinary Bladder: I. Phospholipases and Ca2+ sources, J Pharmacol
Exp Ther (2003). Thus, blockade of L-type Ca.sup.2+ channels has
the potential to depress neural, urothelial and smooth muscle
evoked contractions of bladder strips mediated by a multiplicity of
endogenous GPCR agonists. The L-type calcium channel represents a
point of integration for the convergence of multiple inflammatory
mediators that can lead to hyperactive smooth muscle
contractility.
[0074] Ca.sup.2+ channels located in afferent and efferent nerve
terminals in the lower urinary tract are also important for
regulation of neurotransmitter release. de Groat, W., et al.,
Pharmacology of the Lower Urinary Tract, Annu Rev. Pharmacol
Toxicol. 41:691-721 (2001). A number of active agents produce
Ca.sup.2+ influx and transmitter release from the peripheral nerve
endings of capsaicin-sensitive afferent neurons through
voltage-sensitive Ca.sup.2+ channels. Under certain conditions,
L-type Ca.sup.2+ channels can also contribute to transmitter
release.
[0075] The significant role of the L-type Ca.sup.2+ channel in the
initiation of smooth muscle contraction makes this channel a
potential therapeutic target for the treatment of lower urinary
tract problems that involve hyperactivity or spasm of smooth muscle
tissues. In the presence of inflammatory mediators, signaling
through these same channels may mediate bladder hyperactivity and
spasm.
[0076] An aspect of the present invention is thus directed to
therapeutic compositions including a calcium channel antagonist in
a carrier suitable for delivery to urologic structures in the
urinary tract. The calcium channel antagonist is preferably an
L-type calcium channel antagonist, such as verapamil, diltiazem,
bepridil, mibefradil, nifedipine, nicardipine, isradipine,
amlodipine, felodipine, nisoldipine and nimodipine, as well as
pharmaceutically effective esters, salts, isomers, conjugates and
prodrugs thereof. Still more preferably, the calcium channel
antagonist is a dihydropyridine, such as nifedipine, nicardipine,
isradipine, amlodipine, felodipine, nisoldipine and nimodipine, as
well as pharmaceutically effective esters, salts, isomers,
conjugates and prodrugs thereof. Most suitably, the agent is
nifedipine.
Nifedipine
[0077] References herein to nifedipine,
1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic
acid dimethyl ester, are to be understood to also include
pharmaceutically acceptable isomers thereof, pharmaceutically
acceptable salts or esters thereof, and pharmaceutically acceptable
prodrugs or conjugates thereof. Nifedipine is a preferred calcium
channel antagonist for use in the present invention.
[0078] Nifedipine is a member of the dihydropyridine class of
calcium channel antagonists with pharmacological specificity for
the L-type channel (alternatively termed the Cav1.2
.alpha.-subunit). Nifedipine has a rapid onset of action (less than
10 minutes), which is desirable for use in urological procedures,
and as such is more preferred than certain closely related
dihydropryidine calcium channel antagonists (e.g., amlodipine) that
require longer periods for initial action. The time to response for
steady-state inhibition of muscle contraction ideally occur within
10-15 minutes of initial local drug delivery, and nifedipine
fulfills this criterion.
Carriers
[0079] The pain/inflammation and/or spasm agents of the present
invention are suitably delivered in solution or in suspension in a
liquid carrier, which as used herein is intended to encompass
biocompatible solvents, suspensions, polymerizable and
non-polymerizable gels, pastes and salves. Preferably, the carrier
is an aqueous irrigation solution that may or may not include
physiologic electrolytes, such as saline, distilled water, lactated
Ringer's solution, glycine solutions, sorbitol solutions, manitol
solutions or sorbital/manitol solutions. The carrier may also
include a sustained release delivery vehicle, such as
microparticles, microspheres or nanoparticles composed of proteins,
liposomes, carbohydrates, synthetic organic compounds, or inorganic
compounds.
[0080] The compositions of the present invention may also be coated
on ureteral and urethral stents, catheters, radioactive seeds, seed
spacers and other implantable devices and on surgical instruments,
for local delivery from such devices and instruments into the
urinary tract as further described below. Polymers that may be
suitably employed to form a drug impregnated stent or other
implantable device include, by way of non-limiting example,
poly(D,L-lactic acid) (PDLLA), poly(lactide-co-glyocide) (PLGA),
poly(L-lactic acid) (PLLA), poly(glycolic acid),
poly(6-hydroxycaproic acid), poly(5-hydroxyvaleric acid),
poly(4-hydroxybutyric acid), poly(ethylene glycol), poly(ethylene
oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO,
Pluronics.TM.) block copolymers, and copolymers and blends of the
above.
[0081] Suitable materials for use in producing drug coated stents,
catheters, other implantable devices and instruments include
biodegradable polymers and polymeric hydrogels, such as by way of
nonlimiting example, Pluronics.TM. triblock copolymers, PLLAs or
their copolyesters, poly(glycolic acid) or their copolyesters,
poly(ethylene oxide)-cyclodextrin (polyrotaxan) hydrogels,
poly[(R)-3-hydroxybutyrate]-poly(ethylene oxide)-cyclodextrin
hydrogels, cellulose acetate, cellulose acetate butyrate, cellulose
acetate propionate, and cellulose nitrate; polyurethane resins,
including the reaction product of 2,4-tolylene diisocyanate,
4,4'-diphenylmethane diisocyanate, polymethylenepolyphenyl
isocyanate, or 1,5-napthylene diisocyanate with 1,2-polypropylene
glycol, polytetramethylene ether glycol, 1,4-butanediol,
1,4-butylene glycol, 1,3-butylene glycol,
poly(1,4-oxybutylene)glycol, caprolactone, adipic acid esters,
phthalic anhydride, ethylene glycol, 1,3-butylene glycol,
1,4-butylene glycol or diethylene glycol; acrylic polymers such as
ethyl and methyl acrylate and methacrylate; condensation polymers
such as those produced by sulfonoamides such as toluenesulfonamide
and aldehydes such as formaldehyde; isocyanate compounds;
poly(ortho esters); poly(anhydrides); polyamides;
polycyanoacrylates, poly(amino acids), polycarbonate), cross-linked
poly(vinyl alcohol), polyacetals, polycaprolactone. In addition to
these biodegradable polymers, suitable non-biodegradable polymers
include polyacrylates, polystyrenes, polyvinyl chloride,
ethylene-vinyl acetate copolymers, polyvinyl fluoride, poly(vinyl
imidazole) and chlorosulphonated polyolefins.
[0082] The pain/inflammation and/or spasm inhibitory compositions
of the present invention can also include excipients or adjuvants
for enhanced uptake, release, solubility and stability. Aspects of
formulating the compositions of the present invention are discussed
below.
Additional Agents
[0083] The cyclooxygenase inhibitor, calcium channel antagonist or
combination cyclooxygenase inhibitor plus calcium channel
antagonist compositions of the present invention may include
alternate or additional agents that inhibit pain, inflammation
and/or spasm. Suitable agents include those disclosed in U.S. Pat.
No. 5,858,017 to Demopulos.
[0084] In particular, suitable alternate or additional
anti-inflammation/anti-pain agents include serotonin receptor
antagonists, (e.g., amitriptyline, imipramine, trazodone,
desipramine, ketanserin, tropisetron, metoclopramide, cisapride,
ondansetron, yohimbine, GR127935, methiothepin), serotonin receptor
agonists (e.g., buspirone, sumatriptan, dihydroergotamine,
ergonovine), histamine receptor antagonists (e.g., promethazine,
diphenhydramine, amitriptyline, terfenadine, mepyramine
(pyrilamine), tripolidine), bradykinin receptor antagonists (e.g.,
[Leu.sup.8] des-Arg.sup.9-BK, [des-Arg.sup.10] derivative of HOE
140, [leu.sup.9] [des-Arg.sup.10] kalliden, [D-Phe.sup.7]-BK, NPC
349, NPC 567, HOE 140), kallikrien inhibitors (e.g., aprotinin),
tachykinin receptor antagonists, including neurokinin.sub.1
receptor subtype antagonists (e.g., GR 82334, CP 96.345, RP 67580)
and neurokinin receptor subtype antagonists (e.g., MEN 10.627, L
659.877, (.+-.)-SR 48968), calcitonin gene-related peptide (CGRP)
receptor antagonists [e.g., .alpha.CGRP-(8-37)], interleukin
receptor antagonists, (e.g., Lys-D-Pro-Thr), phospholipase
inhibitors including PLA.sub.2 isoform inhibitors (e.g., manoalide)
and PLC.gamma. isoform inhibitors (e.g.,
1-[6-((17.beta.-3-methoxyestra-1,3,5
(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-dione), lipooxygenase
inhibitors, (e.g., AA 861), prostanoid receptor antagonists
including eicosanoid EP-1 and EP-4 receptor subtype antagonists and
thromboxane receptor subtype antagonists, (e.g., SC 19220),
leukotriene receptor antagonists including leukotriene B.sub.4
receptor subtype antagonists and leukotriene D.sub.4 receptor
subtype antagonists, (e.g., SC 53228), opioid receptor agonists,
including .mu.-opioid, .delta.-opioid and .kappa.-opioid receptor
subtype agonists, (e.g., DAMGO, sufentanyl, fentanyl, morphine, PL
017, DPDPE, U50,488), purinoceptor agonists and antagonists
including P.sub.2X receptor antagonists and P.sub.2Y receptor
agonists, (e.g., suramin, PPADS), adenosine triphosphate
(ATP)-sensitive potassium channel openers, (e.g., cromakalim,
nicorandil, minoxidil, P 1075, KRN 2391, (-)pinacidil), neuronal
nicotinic agonists (e.g.,
(R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594),
(S)-5-(2-azetidinyl-methoxy)-2-chloro-pyridine (S-enatiomer of
ABT-594), 2-methyl-3-(2-(S)-pyrrolidinyl-methoxy)-pyridine
(ABT-089), (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594),
(2,4)-Dimethoxy-benzylidene anabaseine (GTS-21), SBI-1765F,
RJR-2403), 3-((1-methyl-2(S)-pyrrolidinyl)methoxy)pyridine
(A-84543), 3-(2(S)-azetidinylmethoxy)pyridine (A-85380),
(+)-anatoxin-A and (-)anatoxin-A (1R)-1-(9-Azabicyclo
[4.2.2]non-2-en-2-yl)-ethanoate fumarate,
(R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA), cystisine,
lobeline, RJR-2403, SIB-1765F, GTS-21, ABT-418),
.alpha..sub.2-adrenergic receptor agonists [e.g., clonidine,
dexmedetomidine, oxymetazonline,
(R)-(-)-3'-(2-amino-1-hydroxyethyl)-4'-fluoro-methanesulfoanilide
(NS-49), 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino]imidazoline
(AGN-193080), AGN 191103; AGN 192172,
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine
(UK14304),
5,6,7,8-tetrahydro-6-(2-propenyl)-4H-thiazolo[4,5-d]azepin-2-amine
(BHT920),
6-ethyl-5,6,7,8-tetrahydro-4H-oxaazolo[4,5-d]azepin-2-amine
(BHT933), 5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphyl-imidazoline
(A-54741)], mitogen-activated protein kinase (MAPK) inhibitors
(e.g.,
4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole,
[4-(3-iodo-phenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole]-
,
[4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole],
[4-(4-fluoro-phenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole],
2'-Amino-3'-methoxy-flavone), soluble receptors (e.g., tumor
necrosis factor (TNF) soluble receptors, interleukin-1 (IL-1)
cytokine receptors, class I cytokine receptors, and receptor
tyrosine kinases), corticosteroids (e.g., cortisol, cortisone,
prednisone, prednisolone, flurdrocortisone,
6.alpha.-methylprednisolone, tramcinolone, betamethasone,
dexamethasone) and local anesthetics (e.g., benzocaine,
bupivacaine, chloroprocaine, cocaine, etiodocaine, lidocaine,
mepivacaine, pramoxine, prilocaine, procaine, proparacaine,
ropivacaine, tetracaine, dibucaine, QX-222, ZX-314, RAC-109,
HS-37).
[0085] Suitable alternate or additional spasm inhibitory agents
include serotonin receptor antagonists (e.g., amitriptyline,
imipramine, trazodone, desipramine, ketanserin, tropisetron,
metoclopramide, cisapride, ondansetron, yohimbine, GR127935,
methiothepin, oxymetazoline), tachykinin recptor antagonists
including neurokinin.sub.1 receptor subtype antagonists (e.g., GR
82334, CP 96.345, RP 67580) and neurokinin.sub.2 receptor subtype
antagonists (e.g., MEN 10.627, L 659.877, (.+-.)-SR 48968),
adenosine triphosphate (ATP)-sensitive potassium channel openers,
(e.g., cromakalim, nicorandil, minoxidil, P 1075, KRN 2391,
(-)pinacidil), nitric-oxide donors, (e.g., nitroglycerin, sodium
nitroprusside, SIN-1, SNAP, FK 409 (NOR-3), FR 144420 (NOR-4),
endothelin receptor antagonists, (e.g., BQ 123, FR 139317, BQ 610)
and anticholinergics, including antimuscarinics (e.g., ditropan,
tropicamide, cyclopentolate, scopolamine, atropine, homatropine and
oxybutynin), antinicotinics (e.g., trimethaphan, macamylamine,
pentolinium, pempidine and hexamethomium) and first generation
antihistamines (e.g., diphenhydramine).
Methods of Use
Periprocedural Delivery
[0086] Local perioperative delivery of the compositions of the
present invention are expected to preemptively inhibit pain,
inflammation and smooth muscle spasm otherwise associated with
urological procedures. The compositions of the present invention
act on molecular targets, i.e., receptors, enzymes and ion
channels, that initiate pain, inflammation and spasm pathways and
mechanisms. The present invention employs local periprocedural
delivery to inhibit these pathophysiologic processes at the time
they are initiated. For example, multiple proinflammatory peptides
stimulate the release of PGE.sub.2 from bladder tissue within the
first five minutes of exposure, as shown in the examples below.
Solely postprocedurally administered therapeutic agents can only
take effect after these processes have commenced.
Local Delivery
[0087] Local delivery of drugs in accordance with the present
invention permits the utilization of a much lower dosage than would
be needed if the same drugs were administered systemically (e.g.,
orally, intravenously, intramuscularly, subcutaneously) to achieve
the same predetermined local level of inhibitory effect in the
urinary tract. The focused, local delivery of the present invention
results in a significantly lower plasma level of the drug than
would result from systemic delivery of the drug to achieve the same
predetermined local level of inhibitory effect in the urinary
tract, thereby reducing the potential for undesirable systemic side
effects. Local delivery permits the inclusion in the compositions
of the present invention of drugs such as peptides that are not
susceptible to systemic delivery due to degradation during first-
and second-pass metabolism.
[0088] Local delivery of drug compositions in accordance with the
present invention provides for an immediate and certain therapeutic
concentration at the local urinary tract site, which is not
dependent on variations in metabolism or organ function. A constant
concentration of the drugs can be maintained during the period of
delivery of the composition during the procedure.
Urological Procedures
[0089] The compositions of the present invention can be locally
delivered before, during and/or after cystoscopy, i.e., the
endoscopic examination of the urethra and bladder through a
cystoscope inserted into the lower urinary tract for purposes of
examining the urinary tract structures, preferably periprocedurally
during such procedures. The compositions of the present invention
may also be used before, during and/or after (preferably
periprocedurally during) other diagnostic, interventional, medical
and surgical procedures performed in conjunction with cystoscopy,
by insertion of surgical instruments through the cystoscope, such
as for the removal of tissue for biopsy, removal of growths,
removal of foreign bodies, bladder or kidney stone removal,
placement, removal and manipulation of urethral stents,
transurethral resection of bladder tumors (TURBT), treatment of
tumors with electrocautery or laser or local chemotherapeutics,
treatment of bleeding in the bladder or to relieve obstructions in
the urethra.
[0090] The compositions of the present invention can be locally
delivered to the urinary tract before, during and/or after
ureteroscopy, i.e., the endoscopic examination of the ureters and
renal tissues through an ureteroscope inserted through the urethra
and bladder and into a ureter for purposes of examining the urinary
tract structures, preferably periperatively during such procedures.
Ureteroscopy is often performed for the drawing of urine samples
from each kidney, the placement, removal and manipulation of
ureteral stents, as part of the treatment for kidney stones, or to
place a catheter in the ureter for a retrograde pyelography, and
the compositions of the present invention can be delivered before,
during and/or after such procedures, preferable periprocedurally
during such procedures. A basket or other instrument employed via
the ureteroscope can be used to capture the stone, the stone may be
broken up by laser or shock wave lithotripsy through the
ureteroscope, or the ureteroscope may be employed to displace a
lodged stone back into the kidney for subsequent breaking up and
passage, such as by using a laser or extracorporeal shock wave
lithotripsy (ESWL).
[0091] The compositions of the present invention are suitably
locally delivered to the urinary tract before, during and/or after
procedures that typically result in ureteral spasm, such as kidney
stone removal using laser treatment, cystoscopy, ureteroscopy or
lithotripsy, and preferably periprocedurally during such stone
removal procedures.
[0092] The compositions of the present invention may also be
locally delivered to the urinary tract before, during and/or after
(preferably periprocedurally) urological procedures that cause
thermal trauma to tissue in and/or associated with the urinary
tract. These include laser treatment to fragment stones or ablate
tissue, microwave ablation of tissue (e.g., transurethral microwave
thermotherapy (TUMT) to remove prostatic tissue), radiofrequency
ablation of tissue (e.g., transurethral needle ablation (TUNA) to
remove prostatic tissue), electrocauterization or vaporization of
tissue or cryoblation of tissue.
[0093] The compositions of the present invention may also be
locally delivered to the urinary tract before, during and/or after
(preferably periprocedurally) urological procedures employing a
laser for tissue resection, including Holmium:
yttrium-aluminum-garnet (Ho:YAG), neodymium:yttrium-aluminum-garnet
(Nd:YAG) and potassium-titanyl-phosphate (KTP) "green light" laser
therapies. Such laser procedures may include the treatment of
benign prostatic hyperplasia (BPH) and bladder tumors, by way of
non-limiting example.
[0094] The ketoprofen composition, calcium channel antagonist and
ketoprofen combination composition and the preferred ketoprofen and
nifedipine combination composition of the present invention may
also be locally delivered to the urinary tract before, during
and/or after (preferably periprocedurally) transurethral resection
of the prostate (TURP).
[0095] In addition to transurethral procedures such as those
discussed above, the compositions of the present invention may also
be suitably employed for local delivery during other minimally
invasive urological procedures. These include, by way of example,
the transrectal or transperitoneal delivery of the compositions of
the present invention to the prostate and surrounding anatomic
structures during implantation of radioactive seeds and seed
spacers to treat prostate cancer or prostatitis, and the
transrectal or transperitoneal delivery of the compositions of the
present invention to the prostate to treat prostatitis.
[0096] The compostions of the present invention are suitably
locally delivered to the urinary tract before, during and/or after
(preferably periprocedurally) procedures that standardly include
irrigation, such as TURP, transurethral incision of the prostate
(TUIP), laser prostatectomy, cystoscopy, ureteroscopy and other
procedures in which irrigation is used to aid visualization by
removing blood and tissue debris from the operative field. The
compositions of the present invention can be added to the
irrigation solution standardly used in such procedures, e.g.,
saline, distilled water, lactated Ringer's solution, glycine,
sorbitol, manitol, sorbital/manitol, at dilute levels, with no
change to the urologist's standard procedure being required.
[0097] The compositions of the present invention can also be
locally delivered by coating ureteral stents, uretheral stents,
catheters, radioactive seeds, seed spacers or other implantable
devices or surgical instuments, or impregnating or otherwise
incorporating the therapeutic agents into the body of stents,
catheters, radioactive seeds, seed spacers or other implantable
devices or surgical instruments constructed from a polymeric
material or mesh. Techniques for coating devices with drugs and
impregnating devices with drugs are well known to those of ordinary
skill in the art, and coatings or polymeric materials may be
designed to permit the drugs (e.g., a COX inhibitor and a calcium
channel antagonist) to begin releasing into the urinary tract upon
implantation and continuing for a period of time following
implantation.
Formulation
[0098] One aspect of the invention is directed to a composition
including a cyclooxygenase inhibitor and a calcium channel
antagonist, preferably ketoprofen and nifedipine, which are
dissolved in an aqueous solution for parenteral delivery,
preferably for intravesicular delivery. Alternately such
compositions can be manufactured in a lyophilized form and then
reconstituted with an aqueous solvent prior to administration.
[0099] The cyclooxygenase inhibitor and calcium channel antagonist
are suitably included in a molar ratio (cyclooxygenase
inhibitor:calcium channel antagonist) of from 10:1 to 1:10,
preferably from 5:1 to 1:5, more preferably from 4:1 to 1:1, and
most preferably 3:1. Similarly, in a preferred composition
ketoprofen and nifedipine are suitably included in a molar ratio
(ketoprofen:nifedipine) of from 10:1 to 1:10, preferably from 5:1
to 1:5, more preferably from 4:1 to 1:1, and most preferably
approximately (i.e., +/-20%) 3:1.
[0100] For compositions formulated to be delivered locally in a
liquid carrier, the cyclooxygenase inhibitor such as ketoprofen is
suitably included at a concentration (as diluted for local
delivery) of no more than 500,000 nanomolar, preferably no more
than 300,000 nanomolar, more preferably no more than 100,000
nanomolar and most preferably less than 50,000 nanomolar. The
calcium channel antagonist such as nifedipine is suitably included
at a concentration (as diluted for local delivery) of no more than
200,000 nanomolar, preferably no more than 100,000 nanomolar, more
preferably no more than 50,000 nanomolar and most preferably less
than 25,000 nanomolar.
[0101] The compositions of the present invention may be formulated
in an aqueous or organic solvent, but preferably are formulated in
an aqueous solvent. When using aqueous solutions, an additional
solvent or solvents (i.e., cosolvents or solubilizing agents) may
suitably be included to aid in dissolution of the drugs. Examples
of suitable solvents include polyethylene glycol (PEG) of various
molecular weights (e.g., PEG 200, 300, 400, 540, 600, 900, 1000,
1450, 1540, 2000, 3000, 3350, 4000, 4600, 6000, 8000, 20,000,
35,000), propylene glycol, glycerin, ethyl alcohol, oils, ethyl
oleate, benzyl benzoate, and dimethyl sulfoxide (DMSO). A preferred
cosolvent for the compositions of the present invention is PEG,
most preferably PEG 400.
[0102] In a further aspect of the present invention, the
composition includes ketoprofen and nifedipine in an aqueous
solution including at least one stabilizing agent. The term
stabilizing agent is used herein to refer to an agent that inhibits
degradation of the active pharmaceutical ingredients and/or extends
the duration of stability of the solution when stored under either
refrigerated (e.g., 2-8.degree. C.) or ambient temperature
conditions, and includes both anti-oxidants and chelating agents.
The solution may also suitably include one or more cosolvents or
buffering agents. Preferably the aqueous ketoprofen and nifedipine
solution includes one or more antioxidants as stabilizing agent(s),
a cosolvent and a buffering agent. The preferred ketoprofen and
nifedipine solution formulation is stable when stored at between
2.degree. C. and 25.degree. C. for a period of at least six months,
preferably one year, more preferably two years, most preferably
longer than two years, and can be readily diluted with standard
urologic irrigation solutions for local intravesicular delivery
during urological procedures.
[0103] Examples of suitable antioxidants for use as stabilizing
agents in the compositions of the present invention include water
soluble antioxidants such as sodium bisulfite, sodium sulfite,
sodium metabisulfite, sodium thiosulfate, sodium formaldehyde
sulphoxylate, ascorbic acid, acetylcysteine, cysteine,
thioglycerol, thioglycollic acid, thiolactic acid, thiourea,
dithithreitol, and glutathione, or oil soluble antioxidants such as
propyl gallate, butylated hydroxyanisole, butylated hydroxytoluene,
ascorbyl palmitate, nordihydroguaiaretic acid and
.alpha.-tocopherol. A preferred stabilizing agent for the present
invention is propyl gallate. When included in an aqueous
compositon, a cosolvent is included solubilizing oil soluble
antioxidants such as propyl gallate. A preferred aqueous ketoprofen
and nifedipine composition of the present invention includes PEG
400 as a cosolvent and propyl gallate as a stabilizing agent, and
may more preferably also include a second stabilizing agent such as
a water soluble antioxidant, most preferably sodium metabisulfite.
A suitable range of concentrations for antioxidant(s) is typically
about 0.001% to about 5%, preferably about 0.002% to about 1.0%,
and more preferably about 0.01% to about 0.5%, by weight of the
composition.
[0104] Because of the involvement of divalent cations in catalyzing
oxidation reactions, the inclusion of a chelating agent as a
stabilizing agent may be useful in the compositions of the present
invention. Examples of suitable chelating agents for use in the
compositions of the present invention include the various salts of
ethylenediamine tetraacetic acid salts (EDTA),
.beta.-hydroxyethylenediaminetriacetic acid (HEDTA),
diethylenetriamine-pentaacetic acid (DTPA) and nitrilotriacetate
(NTA).
[0105] The compositions of the present invention suitably include a
buffering agent to maintain pH. Examples of suitable buffering
agents for inclusion in the compositions of the present invention
include acetic acid and its salts, citric acid and its salts,
glutamic acid and its salt and phosphoric acid and its salts.
Citric acid also has the ability to chelate divalent cations and
can thus also prevent oxidation, thereby serving two functions as
both a buffering agent and an antioxidant stabilizing agent. A
preferred aqueous ketoprofen and nifedipine composition of the
present invention includes citric acid (such as in the form of
sodium citrate) as a buffering agent and antioxidant, and in a more
preferred composition also includes PEG 400 as a cosolvent and
propyl gallate and sodium metabisulfite as stabilizing agents.
[0106] The compositions of the present invention may also include
additional excipients and adjuvants. Excipients may include a
preservative to protect against microbial growth, especially for
multiple-dose containers. Suitable excipients include antimicrobial
agents such as benzyl alcohol, chlorobutanol, thimiserol, methyl
paraben and propyl paraben. Excipients may also include a
surfactant to reduce surface tension and thereby facilitate wetting
for dissolution. Examples of suitable surfactants include
polyoxyethylene sorbitan monooleate and sorbitan monooleate.
Excipients may also include tonicity adjustment agents to render
the solution iso-osmotic with physiologic fluids. Examples of
suitable tonicity agents include sodium chloride, sodium sulfate,
mannitol, glucose, sucrose, trehalose, and sorbitol. Additional
excipients may include a colorant to impart color, such as FD&
C No. 1 blue dye, FD&C No. 4 red dye, red ferric oxide, yellow
ferric oxide, titanium dioxide, carbon black, and indigo tar
pigments.
TABLE-US-00001 TABLE 1 Exemplary Ketoprofen/Nifedipine Composition
for Delivery to the Urinary Tract (Stock Solution Concentrations
Prior to Dilution) Exemplary Ingredient Function
Concentration/Amount Ketoprofen COX inhibitor 7.63 mg/ml (30 mM)
Nifedipine CA channel antag. 3.46 mg/ml (10 mM) Sodium citrate
Buffered solvent 20 mM solution aqueous solution (pH 6.2 .+-. 0.5)
PEG 400 Solubilizing agent 60% PEG 400:40% Sodium (cosolvent)
citrate soln. (v:v) Sodium metabisulfite Antioxidant 0.02%
(stabilizer) Propyl gallate Antioxidant 0.01% (stabilizer)
[0107] The above concentrated solution is diluted, such as at a
ratio of 1:1,000 (v:v) with standard irrigation solution such as
saline or lactated Ringer's solution. The final dilute solution
from the above exemplary formulation thus includes 0.06% PEG40,
0.00005% sodium metabisulfite and 0.00001% propyl gallate (all by
volume). The active ingredients are present in the final dilute
solution at concentrations of 0.00763 mg/ml (30,000 nM) for
ketoprofen and 0.00346 mg/ml (10,000 nM) for nifedipine.
EXAMPLES
[0108] The present invention may be illustrated by the following
studies demonstrating the effects of ketoprofen and other
cyclooxygenase inhibitors, nifedipine and combinations of these
agents in urological models, and demonstrating the stability of
certain formulations of such compositions.
Example I
The Effect of COX Inhibitors on Bradykinin Induced PGE.sub.2
Production in Rat Bladders
[0109] The following studies evidence that bradykinin induces
immediate prostaglandin E.sub.2 (PGE.sub.2) production in the
bladder, and demonstrate the effects of cyclooxygenase inhibitors
on this process. Bradykinin was chosen as the activating agonist
for testing in this system because its actions on the rat bladder
tissue system have been well characterized and because its role as
a proinflammatory agent in acute pathophysiology has been studied.
Bradykinin is also known to stimulate contraction of smooth muscle
of the bladder when delivered intravesically by activation of B1
and B2 receptor subtypes.
1. Introduction
[0110] Acute, localized inflammatory responses in the lower urinary
tract, including spasm, are triggered by surgical trauma. In
response to tissue injury, multiple inflammatory mediators,
including bradykinin and Substance P (SP) are released into the
bladder. Exogenous application of these pro-inflammatory peptides
or activation of bladder nerves can trigger the production of
prostaglandins (PGs) in the bladder. The aim of this study was to
characterize the time course of production of PGs in response to an
inflammatory mediator and evaluate the effects of COX-1/COX-2
inhibitors on bladder tissue contractility in vitro and in vivo.
The rat bladder tissue strip system represents a well established
system for characterization of the pharmacological actions on
numerous agents on smooth muscle bladder contractility [Edwards,
G., et al., Comparison of the Effects of Several Potassium-Channel
Openers on Rat Bladder and Rat Portal Vein In Vitro, Br. J.
Pharmacol. 102:679-80 (1991); Birder, L., et al.,
.beta.-adrenoceptor Agonists Stimulate Endothelial Nitric Oxide
Synthase in Rat Urinary Bladder Urothelial Cells, J. Neurosci.
22:8063-70 (2002)].
2. Bladder Strip Contractility
Method
[0111] Isolated bladder smooth muscle strips of 1.times.2.times.15
mm dimension were obtained from Wistar derived male or female rats
weighing 275.+-.25 g that were sacrificed by CO.sub.2 overexposure.
Each strip was placed under 1 g tension in a 10 ml bath containing
Krebs solution with 1 .mu.M enalaprilic acid (MK-422), composition
(g/l): NaCl 6.9, KCl 0.35, KH.sub.2PO.sub.4 0.16, NaHCO.sub.3 2.1,
CaCl.sub.2 0.28, MgSO 4.7, H.sub.2O 0.29, (+)Glucose 1.8, pH 7.4
bubbled with 95% O.sub.2/5% CO.sub.2 at 32.degree. C. Each strip
was connected to an isometric transducer (Harvard, #50-7293) and
two-pen recorder and allowed to equilibrate for 60 minutes. Before
starting the experiment, mounted tissues were validated for
acceptance by challenge with 100 .mu.M of methoxamine to obtain a
minimum of 1 g tension, which was considered as 100%. Qualified
tissues were washed repeatedly every 15 minutes for 60 minutes. A
cumulative contraction-response curve to bradykinin was then
generated through application of 3 concentrations of bradykinin
(0.01 .mu.M, 0.1 .mu.M and 1 .mu.M) at 1 minute intervals for a
total of 3 minutes. The tissue was subsequently washed periodically
until tension returned to baseline value. Two hours later, the
ability to inhibit the bradykinin cumulative dose response (0.01
.mu.M, 0.1 .mu.M and 1 .mu.M) after a 10 minute pretreatment with
ketoprofen was determined. Each concentration of test substance was
tested in four separate preparations.
Results
[0112] FIG. 2 illustrates the cumulative concentration-response
curves of normal animals to the agonists bradykinin and SP. The
EC.sub.50 for bradykinin was 8.5 nM and for SP was 6.5 nM. This
provided a validated system for testing the effects of the
inhibitory activity of NSAIDs (COX inhibitors).
[0113] FIG. 3A illustrates bradykinin concentration-response curves
produced in the presence of 0.25, 1.0, 2.5 and 10 .mu.M ketoprofen.
The maximal agonist response could not be determined experimentally
for all concentrations of ketoprofen, although curve-fitting using
a standard Hill equation revealed no change in maximal response at
saturating agonist concentrations. Schild analysis was used to
calculate the pA.sub.2 value of 7.26 for ketoprofen, equivalent to
a K.sub.D for ketoprofen at its site of action of
5.52.times.10.sup.-8 M (see FIG. 3B). This finding demonstrates
that the potency for inhibition in this tissue assay system is
quite comparable to values obtained from direct enzyme inhibition
assays.
3. PGE.sub.2 Determination
Methods
[0114] The release of PGE.sub.2 from urinary bladder strips into 10
ml of tissue bath was measured using a specific enzyme immunoassay
(EIA) according to the manufacturer's instructions (Amersham
Pharmacia Biotech) for the basal, bradykinin-induced and COX
inhibitor treatment plus bradykinin-induced samples. The COX
inhibitors tested were ketoprofen, flurbiprofen,
5-bromo-2-(4-fluorophenyl)-3-(4-methylsulfonyl) thiophene (i.e.,
DUP-697) and
1-[(4-methysufonyl)phenyl]-3-tri-fluoromethyl-5-(4-fluorophenyl)pyrazole
(i.e., SC-58125). One mL of fluid was collected from the 10 mL
tissue bath after 10 minutes of bradykinin challenge for PGE.sub.2
determination. Samples were frozen immediately and stored at
-4.degree. C. until assay. The bladder strips were dried gently by
blotting and were then weighed. Results are expressed as picograms
of PGE.sub.2 released per milligram tissue.
Results
[0115] FIG. 4A illustrates that bradykinin rapidly induces the
formation of PGE.sub.2 in rat bladder tissue strips within the
first minutes of stimulation and reaches a maximum within 30
minutes. The t.sub.1/2 for formation was about 7.5 minutes. FIG. 4B
illustrates the rapid kinetics of PGE.sub.2 formation detected
within the first ten minutes.
[0116] Ketoprofen inhibition of bradykinin-induced bladder strip
contraction was closely correlated with inhibition of PGE.sub.2
formation, as shown in Table 2. Non-selective COX-1/COX-2
inhibitors were found to be effective in blocking
bradykinin-stimulated PGE.sub.2, while COX-2 selective agents were
not effective. This corresponds to a lack of COX-2 inhibitor
activity under bradykinin-induced normal cystometry parameters.
TABLE-US-00002 TABLE 2 Inhibition of Bradykinin (BK)-induced
Contraction with COX Inhibitors BK-induced Contraction BK-induced
PGE.sub.2 Drug IC50 (.mu.M) IC50 (.mu.M) Ketoprofen 0.97 0.58
Flurbiprofen 24.8 1.65 DUP-697 >25 >25 SC-58125 >25
>25
[0117] FIG. 1 (described previously) provides a model for action of
prostaglandin activity. Activation of bradykinin receptors on
urothelial cells may produce PGs in the urothelium, which in turn
may activate bladder nerves (C-fiber and M fibers) to affect
bladder contractility and control micturition reflexes. Ketoprofen
inhibits formation of PGE.sub.2.
4. In Vivo Rat Cystometry Model
Methods
[0118] The rats were anesthetized with urethane at 1.2 g/kg i.p. in
5 ml/kg. A polyethylene catheter (PE50) was implanted into the
bladder for saline or acetic acid infusion through a 3-way
stopcock. A pressure transducer was connected for measurements of
intravesical pressure. Warm (37.degree. C.) saline was infused into
the bladder at a constant rate of 16.7 ml/min (1 ml/hour) until
cystometry became stable (no less than 60 minutes). Thereafter,
0.2% acetic acid was infused into the urinary bladder. Aspirin (10
mg/kg i.v.) and vehicle were administered intravenously via a PE-10
catheter in the femoral vein at 5 minutes after infusion of acetic
acid was started and at the end of first micturition cycle.
Dunnett's test was applied for comparison between the time before
and after test substance or vehicle treatment. To ascertain
differences between the test substance and the vehicle control
group, an unpaired Student's t test was used. Differences are
considered significant at p<0.5.
Results
[0119] FIG. 5A illustrates that intravenous aspirin (10 mg/kg)
produced a gradual time-dependent inhibition of the acetic acid
induced reduction in the intercontraction interval (ICI), and FIG.
5B illustrates the parallel changes in bladder capacity. Threshold
pressure and micturition pressure were not affected by aspirin
treatment (data not shown).
6. Discussion
[0120] These studies demonstrate that PGE.sub.2 is rapidly produced
in rat bladder tissue following stimulation with bradykinin and
that its formation is inhibited by a 10 minute pre-incubation with
ketoprofen. Non-selective COX-1/COX-2 inhibitors were demonstrated
simultaneously to have blocked the rapid production of PGs in
bladder tissue and tissue contractility. Aspirin and other
non-selective COX-1/COX-2 inhibitors effectively inhibited
cystometric changes induced by intravesical acetic acid
stimulation. These studies suggest that delivery of ketoprofen to
the urinary tract may be therapeutically beneficial for
periprocedural bladder hyperactivity.
Example II
Effects of Ketoprofen and Nifedipine Individually on Bradykinin
Induced Contractility in Rat Bladder Tissue Strips
[0121] The purpose of this study was to characterize the effects of
ketoprofen, a non-selective COX-1/COX-2 inhibitor, and nifedipine,
an L-type Ca.sup.2+ channel antagonist, on agonist-stimulated rat
bladder contractility using bradykinin as a stimulating
agonist.
1. Methods
[0122] Ketoprofen USP and nifedipine USP were dissolved in DMSO
prior to dilution to the final concentration. Bladder tissue strips
from Wistar derived rats were prepared, transduced and equilibrated
using the bladder strip contractility method described in Example I
above. Assayed tissue was incubated with the test drugs for 10
minutes before activities were determined.
[0123] A cumulative contraction-response curve to bradykinin was
generated through application of 7 bradykinin concentrations in
3-fold increments ranging from 0.001 .mu.M to 1 .mu.M at 1 minute
intervals for a total of 7 minutes to establish the maximal 100%
control response. The tissue was subsequently washed periodically
until tension returned to baseline value. In 24 separate tissues,
similar bradykinin concentration-responses were carried out in the
presence of each respective test compound (ketoprofen: 0.25 .mu.M,
1 .mu.M, 2.5 .mu.M and 10 .mu.M; nifedipine: 0.125 .mu.M, 0.5
.mu.M, 1.25 .mu.M and 5 .mu.M) following a 10 min incubation
period. Tissue strips were always used in pairs for the study of
the action of the antagonist (bradykinin) alone and in the presence
of a concentration of antagonist (ketoprofen or nifedipine). Schild
plots were obtained using computer software (Pharmacology
Cumulative System, Version 4) and pA.sub.2 values were
determined.
2. Results
[0124] Nifedipine was found to exhibit a noncompetitive type of
antagonism upon bradykinin-induced contractile responses in the in
vitro rat bladder preparation. This was shown by a depression of
the maximum agonist response and a small non-parallel rightward
shift of the agonist concentration response curves (FIG. 6). In
contrast, as previously described in Example I, increasing
concentrations of ketoprofen (0.25-10 .mu.M) produced a series of
concentration-response curves (see FIG. 3A) in which the EC.sub.50
agonist response moved progressively to higher concentrations of
bradykinin (shift to the right of over 2 orders of magnitude) with
no apparent effect on maximal tension. This pattern of inhibition
is consistent with a competitive mechanism for ketoprofen and was
further analyzed by Schild regression analysis.
[0125] For nifedipine, the criteria for application of the Schild
regression analysis were not met due to the noncompetitive pattern
of inhibition. Even the lowest concentration of nifedipine (0.125
.mu.M) resulted in a large reduction in the agonist response (to
about 50% of maximum). These studies of ketoprofen and nifedipine
reveal two very different patterns of inhibition of
bradykinin-stimulated contractile tension.
Example III
Effects of Ketoprofen and Nifedipine Combination on Bradykinin
Induced Contractility in Rat Bladder Tissue Strips
[0126] The present study evaluated the effects of nifedipine and
ketoprofen administered in combination on the contractile tension
response in a rat bladder tissue strip model.
1. Methods
[0127] Bladder tissue strips from Wistar derived rats were
prepared, transduced and equilibrated using the bladder strip
contractility method described in Example I above with transduced
strips being allowed to equilibrate for 45 minutes. In order to
avoid effects of bradykinin receptor desensitization from the
cumulative dosing protocol, two tissue strips were collected from
each animal. The control group consisted of 12 strips and 54 strips
were used for the treatment groups.
[0128] Before starting the experiment, each pair of tissue strips
was qualified by treating with 0.03 .mu.M bradykinin to determine
if the initial difference in maximal contraction between strips was
within +/-15%. Following this procedure, qualified tissues were
washed repeatedly every 15 minutes for 60 minutes. Cumulative
concentration-response curves were generated by application of
bradykinin to establish maximal response. For the control group
(n=12), a cumulative concentration-response curve to bradykinin was
then generated through application of nine concentrations from 0.1
nM to 1.0 .mu.M in 3-fold steps at one minute intervals, for a
total of nine minutes to establish the maximal 100% control
response. Response curves for the treatment groups involved
pre-incubation of the bladder tissue for a period of ten minutes
(n=6), followed by generation of bradykinin cumulative
dose-response curves by application of 12 concentrations of
bradykinin (0.1 nM-30 .mu.M).
[0129] The concentration range that was chosen for each of the
active agents was based upon results from prior in vitro
pharmacological studies of each single agent described in Examples
I and II above. Those studies showed that ketoprofen in the 0.3-3
.mu.M range had measurable effects on the EC.sub.50 for bradykinin
activation. Ketoprofen at 3 .mu.M was near maximal in its ability
to shift the EC.sub.50 of the bradykinin activated response curves
on muscle contractility. Similarly, prior testing of nifedipine
identified a range of concentrations (0.05-5 .mu.M) effective at
inhibiting bradykinin induced tension. A factorial design
characterized the effects of nine different two-drug combinations
of ketoprofen and nifedipine at the following concentrations of (i)
ketoprofen: 0.3, 1.0, or 3.0 .mu.M; and (ii) nifedipine: 0.1, 0.3
or 1.0 .mu.M. The treatment groups (groups 2-10) tested are
summarized in Table 3 below:
TABLE-US-00003 TABLE 3 Ketoprofen-Nifedipine Combinations Tested
Group Ketoprofen Conc. (.mu.M) Nifedipine Conc. (.mu.M) 1 (Control)
-- -- 2 0.3 0.1 3 0.3 0.3 4 0.3 1.0 5 1.0 0.1 6 1.0 0.3 7 1.0 1.0 8
3.0 0.1 9 3.0 0.3 10 3.0 1.0
[0130] The bradykinin concentration-response data was fit to a
variable slope sigmoidal equation, also known as the 3-parameter
logistic response (3PL) function, to obtain the maximal tension,
EC.sub.50, and Hill slope in which the bottom of the curve was
fixed at 0. The force of contraction in the presence of inhibitors
was expressed as a percentage of the maximum bradykinin effects
observed within the same strip before addition of an inhibitor.
2. Results
[0131] The experimental data for all curves allowed curve fitting
to accurately define the maximal tension and EC.sub.50 values. The
control curve in FIG. 7 showed that BK concentration-dependently
increased the force of contraction with a pEC.sub.50 of 8.14 or 72
nM (n=12 strips). A moderate Hill slope of 0.65 characterized the
activation curve. All further contraction data was expressed as a
percentage of the maximum bradykinin effect obtained from a set of
12 tissue strips without any tension and without any antagonist
present.
[0132] The results for nine distinct combinations of nifedipine and
ketoprofen used to inhibit bradykinin-induced bladder contraction
are shown in the following three tables and three figures. At the
lowest concentration of nifedipine and ketoprofen tested, 0.1 .mu.M
and 0.3 .mu.M respectively, 38% reduction of the maximal control
tension was observed (Table 4). Increasing concentrations of
ketoprofen (1.0 and 3.0 .mu.M) in the presence of the same
concentration of nifedipine further decreased the maximal
contractile tension such that only 30 and 23.4% of the control
tension remained, respectively. All concentration-response curves
for bradykinin shifted to the right in the presence of nifedipine
and ketoprofen (0.3-3.0 .mu.M), with the greatest effect seen at
the highest ketoprofen concentration. This combination was
accompanied by a 1.0 log unit shift in the pEC.sub.50 versus
control. The changes in the EC.sub.50 parameter did not appear
correlated with changes in maximal tension. The results are
presented graphically in FIG. 7, which compares the control group
and the group having a constant concentration of 0.1 nifedipine
with a range of concentrations of ketoprofen. The percent of
contraction for each drug combination is expressed as the percent
of the maximal response for the bradykinin control. The overall
pattern of inhibition predominantly reflects a substantial decrease
in maximal tension, demonstrating that the combination of
nifedipine and ketoprofen act together in combination
mechanistically in a non-competitive antagonist manner towards
bradykinin-induced contractions.
TABLE-US-00004 TABLE 4 Concentration-Response Curve Fitted
Parameters for 0.1 .mu.M Nifedipine (NIF) plus 0.3-3.0 .mu.M
Ketoprofen (KET) T.sub.max Log EC.sub.50 Hill Slope Concentration
of Drug Est. SEM Est. SEM Est. SEM Control 100.00 4.17 -8.14 0.09
0.65 0.07 0.1 .mu.M NIF + 0.3 .mu.M KET 62.11 3.90 -7.61 0.18 0.69
0.16 0.1 .mu.M NIF + 1.0 .mu.M KET 30.13 1.92 -7.95 0.17 1.02 0.35
0.1 .mu.M NIF + 3.0 .mu.M KET 23.38 2.24 -7.02 0.24 0.62 0.16 Est.
= Estimated SEM = Standard error of the mean T.sub.max = Maximal
tension determined by curve fitting
[0133] In the presence of 0.3 .mu.M nifedipine, increasing
concentrations of ketoprofen present in the combination treatment
resulted in a progressive decrease in the maximal tension, from
36.4 to 16.0%. Combinations utilizing the higher concentration of
nifedipine (0.3 .mu.M) resulted in a greater reduction in the
maximal tension relative to the corresponding concentrations of
ketoprofen in the presence of 0.1 .mu.M nifedipine. The maximal
tension levels for 0.3 .mu.M nifedipine combinations were
determined for three combinations, in concentration ratios of
nifedipine:ketoprofen of 1:1, 1:3.3 and 1:10. The curve fitted
parameters data obtained are presented in Table 5.
[0134] Comparison to data corresponding to ketoprofen
concentrations in Table 4 shows that in all cases, greater
reductions in the maximal tension were associated with the greater
nifedipine concentration. The greatest change was evident at the
lowest ketoprofen concentration, 0.3 .mu.M, which decreased from
62.11 to 36.41%. The higher concentrations of ketoprofen resulted
in an even greater reduction in tension, such that only 16%
remained at 3.0 .mu.M. Associated with these changes in tension, a
similar shift in the EC.sub.50 relative to the control of 0.5 log
units was evident for all ketoprofen concentrations at this
nifedipine concentration, as can be seen in FIG. 8. As in the case
of 0.1 .mu.M nifedipine, no apparent differences between the
EC.sub.50 values for this concentration of nifedipine were evident.
Small differences in the Hill slopes for bradykinin agonist
responses over the range of inhibitor concentrations were not
significant. The effect of increasing ketoprofen concentrations in
the combination treatment on the concentration-response curves is
similar to the graph of the data at 0.1 .mu.M nifedipine and
various ketoprofen concentrations. These graphical data also show
the non-competitive nature of the antagonism of the BK-response,
which is seen for the combination at this higher concentration of
nifedipine.
TABLE-US-00005 TABLE 5 Concentration-Response Curve Fitted
Parameters for 0.3 .mu.M Nifedipine (NIF) plus 0.3-3.0 .mu.M
Ketoprofen (KET) T.sub.max Log EC.sub.50 Hill Slope Concentration
of Drug Est. SEM Est. SEM Est. SEM Control 100.00 4.17 -8.14 0.09
0.65 0.07 0.3 .mu.M NIF + 0.3 .mu.M KET 36.41 3.84 -7.49 0.29 0.66
0.24 0.3 .mu.M NIF + 1.0 .mu.M KET 28.88 2.24 -7.69 0.22 0.72 0.21
0.3 .mu.M NIF + 3.0 .mu.M KET 15.96 1.82 -7.59 0.29 0.94 0.51 Est.
= Estimated SEM = Standard error of the mean T.sub.max = Maximal
tension determined by curve fitting
[0135] The overall shapes of the response curves observed in the
presence of 1.0 .mu.M nifedipine were similar at all concentrations
of ketoprofen. At 1.0 .mu.M nifedipine, the maximal tension levels
were less than the corresponding values for 0.3 .mu.M nifedipine
(Table 6 and FIG. 9), and the magnitude of the additional change
due to the presence of ketoprofen is less relative to lower
concentrations of nifedipine. The EC.sub.50 values were uniformly
shifted about 0.51 units for all ketoprofen concentrations and were
not correlated with maximal tension. This pattern was consistent
with observations at all other combination concentrations. A small
additional increase in the inhibition of maximal tension due to the
change from 1.0 to 3.0 .mu.M ketoprofen was observed at this
highest concentration of nifedipine. At the highest concentrations
(1.0 .mu.M nifedipine plus 3.0 .mu.M ketoprofen), 89% inhibition of
the control tension level was achieved.
TABLE-US-00006 TABLE 6 Concentration-Response Curve Fitted
Parameters for 1.0 .mu.M Nifedipine (NIF) plus 0.3-3.0 .mu.M
Ketoprofen (KET) T.sub.max Log EC.sub.50 Hill Slope Concentration
of Drug Est. SEM Est. SEM Est. SEM Control 100.00 4.20 -8.14 0.09
0.65 0.07 1.0 .mu.M NIF + 0.3 .mu.M KET 21.60 1.00 -7.50 0.12 0.93
0.20 1.0 .mu.M NIF + 1.0 .mu.M KET 12.30 1.00 -7.48 0.20 0.96 0.35
1.0 .mu.M NIF + 3.0 .mu.M KET 10.80 0.80 -7.34 0.16 1.08 0.37 Est.
= Estimated SEM = Standard error of the mean T.sub.max = Maximal
tension determined by curve fitting
3. Response Surface Analysis
[0136] The concentrations of the two agents (nifedipine and
ketoprofen) used in this combination experiment represent
independent variables. The maximal tension is an effect that
results from the combination and is the response variable of
primary interest for the response surface analysis. The
relationship between the drug combinations and the response
variable can be represented in a three-dimensional plot in which
the concentrations are plotted as Cartesian coordinates in the
x-y-plane, and the response variable (e.g., maximal tension) is
plotted as the vertical distance above the planar point. The
collection of spatial points plotted in this way provides a view
that represents the combined concentration-response relationship.
The advantages of this experimental design method include the fact
that the biological response measured is not limited to a specific
response (effect) level of the system. In this way, a number of
fixed-ratio concentration combinations can be tested over a wide
range of concentrations to define the interaction efficacy of the
two drugs.
[0137] As in the case of single drug concentration-biological
effect relationships in which a smooth curve (or line) may be best
fit to the data according to a specific model, a smooth surface may
be fit to the data in a three-dimensional plot of a two-drug
combination concentration-response relationship. This surface
represents the additivity or interaction of the combination. The
graph of this response surface becomes the reference surface for
viewing actual combination effects and allows the visualization and
prediction of effects in regions of the curve for which no data
could be generated.
[0138] A standard response surface analysis was performed on the
estimated maximal tension and EC.sub.50 values. The response
surface model was fitted using as a response variable the tension
values at the highest agonist concentration on each individual dose
response curve, which was the tension corresponding to 30 .mu.M BK.
FIG. 10 shows the fitted response surface for the reduced model as
a function of ketoprofen and nifedipine concentration. The
combination response curve drops steeply with increasing
concentrations of both ketoprofen and nifedipine. The surface
becomes fairly flat as the maximal response is obtained as
concentrations approach 1 .mu.M nifedipine+3 .mu.M ketoprofen. The
concentration combination that results in 90% maximal inhibition of
the effect of bradykinin is 3 .mu.M of ketoprofen+1 .mu.M of
nifedipine.
4. Discussion
[0139] The study of this Example III evaluated the effects of
nifedipine in combination with ketoprofen using bradykinin as an
agonist to stimulate smooth muscle contraction. Bradykinin was used
in the rat bladder tissue strip assay system (Examples I-III) to
serve as an endogenous mediator of contraction. The overall pattern
of inhibition seen with all combinations of nifedipine and
ketoprofen concentrations was characteristic of non-competitive
antagonism. Nifedipine, which prevents the influx of calcium ions
through the cell membrane by acting on L-type voltage-dependent
channels, attenuates the bradykinin receptor activated contraction
of smooth muscle without directly inhibiting the receptor. As a
single agent, nifedipine inhibition was shown above (Example II) to
cause a reduction in the maximum bradykinin responses that were not
accompanied by statistically significant changes in the agonist
potency of the remaining response.
[0140] This study revealed the surprising finding that the
magnitude of the inhibition is greatly enhanced by the addition of
ketoprofen at the lowest nifedipine concentration tested and is
evident at all concentrations of the combinations tested. At low
concentrations of nifedipine, this inhibition is more than
additive, i.e., synergistic in nature. In contrast, ketoprofen
treatment alone at the same concentrations was observed to not
decrease maximal contractile tension, with no signficant effect on
the EC50 values for the nine combinations and no concentration
dependence upon ketoprofen. Thus, this synergistic interaction on
maximal tension and lack of strong effect upon the EC50 was an
unexpected result based on the study of ketoprofen action when
tested as a single agent in this test system.
[0141] Taken together, these data indicate that the effects of the
proinflammatory agonist, bradykinin, can be in part mediated by the
simultaneous activation of L-type calcium channels and the
induction of arachidonic metabolites that together augment smooth
muscle contraction. While not wishing to be limited by theory, this
effect may be due to a positive feedback loop that operates at a
cellular and tissue level. Prostaglandins generated intracellularly
as a result of bradykinin receptor activation may move to the
extracellular environment, where they may interact and in turn
activate prostanoid receptors subtypes. There are at least four
known prostanoid receptor subtypes, termed EP1, EP2, EP3 and EP4.
Of these subtypes, EP1 receptors are believed to be coupled through
G proteins to stimulation of phophoinositide hydrolysis and/or
PLC-independent influx of calcium. EP1 receptors have been
previously identified in smooth muscle, where they can function to
mediate contractile activity. Hence, the discovery of the combined
synergistic actions of ketoprofen and nifedipine on contractile
activity may be a result of simultaneous blockade of calcium
mobilization and the concurrent inhibition of a positive-feedback
loop involving PGE.sub.2 driven activation of prostanoid
receptors.
[0142] In conclusion, each combination of nifedipine and ketoprofen
showed a greater inhibition of maximal bradykinin-induced
contraction compared to either drug alone in the rat bladder tissue
strip assay. Furthermore, the multiple combinations of nifedipine
and ketoprofen tested allowed a response surface analysis to define
optimal concentrations. A fixed ratio combination containing 3.0
.mu.M ketoprofen and 1.0 .mu.M nifedipine was identified that
produced .about.90% inhibition.
Example IV
Inhibition by Nifedipine and Ketoprofen of Multiple Agonist-Induced
Contractile Tension and Release of PGE.sub.2 in Rat Bladder
Tissue
[0143] The objective of this study was to evaluate the effects of
ketoprofen and nifedipine on rat bladder contractility and
agonist-stimulated PGE.sub.2 production using multiple agonists.
Bradykinin, substance P, histamine and ATP are endogenous mediators
that can be released as part of the acute inflammatory response and
activate bradykinin receptors (B1 and B2 subtypes), tachykinin
receptors (NK.sub.1-3) and histamine receptors (all subtypes) and
purinergic P2X and P2Y receptors, respectively. Carbamylcholine is
an agonist that may activate muscle and neuronal nicotinic
acetylcholine subtypes or muscarinic acetylcholine receptors
subtypes (M.sub.1-5) present in the bladder, while methoxamine is
specific for .alpha..sub.1-adrenergic receptors. The first
objective was to evaluate the effect of ketoprofen (10 .mu.M) and
nifedipine (1 .mu.M) individually, each at a fixed concentration,
on contractile tension induced by each of the six agonists
(bradykinin, substance P, carbamylcholine, methoxamine, histamine
and ATP) in the rat bladder tissue strip model. The second
objective was to determine the amount of PGE.sub.2 released from
the bladder tissue in response to stimulation by each agonist in
the presence of either ketoprofen or nifedipine during the same
test conditions employed to measure contractile smooth muscle
tension.
1. Methods
[0144] Bladder tissue strips from Wistar derived rats were
prepared, transduced and equilibrated using the bladder strip
contractility method described in Example I above. Either 10 .mu.M
ketoprofen or 1.0 .mu.M nifedipine was pre-incubated individually
with the tissue for a period of 10 minutes prior to stimulation
with the following agonists at a concentration equivalent to its
respective ED.sub.75 for stimulation of tension: 0.03 .mu.M
bradykinin; 0.03 .mu.M substance P; 3.0 .mu.M carbochol; 30 .mu.M
methoxamine; 25 .mu.M histamine; and 20 .mu.M ATP. Antagonist
activity for a given concentration of an antagonist (nifedipine or
ketoprofen) was determined as the ability of that concentration of
the antagonist to reduce the noted agonist-induced (e.g., 0.03
.mu.M bradykinin-induced) response by 50 percent or more
(.gtoreq.50%). Each concentration of antagonist was tested in four
separate tissue preparations.
[0145] The effects of the two drugs on PGE.sub.2 release in
response to multiple agonists was compared using the same 10 min
pre-incubation protocol and a subsequent 30 min incubation period
with agonist in the presence of the test compound. PGE.sub.2
produced after 30 minutes of treatment with each agonist (e.g.,
0.03 .mu.M bradykinin) in the absence and presence of the test
compounds was determined. An initial 1.0 ml sample was taken from
the tissue bath after a 30 minute incubation with the agonist.
Subsequently, the tissue was washed using 10 ml of Krebs solution
every 15 minutes for a 2 hour period. The test compound was added
and pre-incubated for a period of 10 minutes prior to re-challenge
with the same agonist. After an additional 30 minute period in the
presence of the test antagonist and agonist, 1.0 ml was removed
from the bath for analysis. The release of PGE.sub.2 from urinary
bladder strips was measured using a specific enzyme immunoassay
(EIA). Samples were frozen immediately and stored at -4.degree. C.
until assay. The bladder strips were dried gently by blotting, and
then weighed. Results are expressed as picograms of PGE.sub.2
released per milligram tissue.
2. Results
[0146] All of the agonists investigated stimulated contraction of
the bladder tissue strips, independent of their mechanism of
action, demonstrating that multiple mediators can increase bladder
smooth muscle contractile tension. Nifedipine (1 .mu.M) produced a
significant inhibition (>67%) of each agonist-induced increase
in contractile tension (FIG. 11). The contractile response to
bradykinin was affected by both nifedipine and ketoprofen (81%
inhibition and 67% inhibition, respectively). In contrast, the
increase in contractile tension induced by substance P,
carbamylcholine and ATP was not affected by ketoprofen. Ketoprofen
also only slightly reduced the tension for methoxamine and
histamine (<25%).
[0147] Bradykinin evoked the largest increase in PGE.sub.2 relative
to the other agonists tested. This evoked release was effectively
inhibited by ketoprofen (81%) but minimally affected by
pre-treatment with nifedipine (12%) (FIG. 12). Thus, the extent of
inhibition of smooth muscle tension by nifedipine was not linked to
agonist-induced PGE.sub.2 responses and was distinct from the
effect of ketoprofen. The absolute bladder levels of PGE.sub.2
produced in response to stimulation by other GPCR agonists were
about 10-fold less than those seen with bradykinin.
[0148] In summary, the current study indicated that an increase in
smooth muscle contractile tension can be induced by a variety of
GPCR agonists in bladder tissue. Moreover, a common signaling
mechanism for these agents is mediated in part through activation
of L-type Ca.sup.2+ channels in the rat urinary bladder.
Nifedipine's inhibition of L-type Ca.sup.2+ channels suggests an
effective mechanism for inhibition of numerous pathophysiological
mediators that can lead to increased smooth muscle bladder tension
associated with spasm or hyperactivity. Ketoprofen inhibited
bradykinin-stimulated PGE.sub.2 production and release from the
bladder while nifedipine did not exhibit an effect on this
response. Thus, nifedipine and ketoprofen act through distinct
mechanisms to inhibit smooth muscle contractile tension and release
of pro-inflammatory prostaglandins in bladder tissue.
Example V
Effect of Ketoprofen and Nifedipine on Rat Bladder Function in an
Acetic-Acid Overactive Bladder Model
[0149] The primary objective of this study was to measure the
effect of ketoprofen and nifedipine during intravesical, local
delivery to female rats with overactive bladder function caused by
perfusion with saline containing 0.2% acetic acid (acidified
saline). Perfusion of 0.2% acetic acid through the bladder is known
to rapidly induce an acute inflammatory state that is reflected in
functional changes in bladder cystometry.
1. Methods
[0150] The method used in the current study represents an
adaptation of a widely used acetic acid-triggered rat model of
hyperactive bladder. In this model, acute inflammation of the
bladder is produced by using 0.2% acetic acid in saline as the
bladder perfusion fluid and cystometry under anesthesia is
performed after a recovery period from the surgical procedure. A
regular interval of voiding cycles can be seen for several hours
after the initial stabilization period occurs. A bladder catheter
connected to an infusion pump was used to deliver the drug
solutions directly to the bladder at a constant, defined rate.
[0151] The animals were anesthesized and bladder catheters were
surgically implanted to allow irrigation of the test agents. The
following cystometry parameters were monitored: intercontraction
interval (ICI), trigger pressure (TP), micturition pressure (MP)
and micturition volume (MV) using a Med Associates Cystometry
Station and software program. Only rats that displayed normal and
stable cystometry profiles during the preliminary saline-infusion
stage (not less than 15 min of baseline stabilization followed by 7
regular representative ICI intervals) were included in the study.
Following the saline period, the rat bladder was infused with test
agent in saline containing 0.2% acetic acid for 20 min followed by
the collection of 7 representative ICI intervals for analysis. Due
to the fixed concentrations of the irrigation solutions employed in
the study and the use of constant perfusion rates for fixed
constant times, a fixed, uniform dose of each agent was delivered
to all animals.
[0152] Groups of female rats were administered ketoprofen at
selected concentrations (0.01-25 .mu.M) alone or nifedipine at
selected concentrations (0.1-10 .mu.M) alone. Five to seven animals
were normally tested in each group. Acidified saline served as the
control. All infusion solutions were prepared fresh on the day of
the experiment before use. For each of the test agents, three
distinct bladder irrigation periods were employed: 1) baseline
(saline only) for 1 hour; 2) drug in saline only for 15 minutes;
and 3) drug in 0.2% acidified saline for 1 hour.
2. Results
[0153] In the control animals, baseline levels of bladder
contractions in response to a constant irrigation rate of 0.1
.mu.l/min saline were established during the first hour following
surgery. The time between contractions (ICI, seconds) and peak
micturition pressure (MP, mm Hg) appeared to vary somewhat between
animals but was fairly constant within animals following
stabilization. Following the addition of the 0.2% acetic acid to
the perfusion buffer, rapid contractions appeared, resulting in a
significant decrease in the ICI. Increases in contractile pressure
accompanied the shortening of time between the bladder contractions
in many cases as well. These changes in functional bladder
responses could be routinely measured following perfusion of the
bladder with acidified saline, as shown in FIG. 13. A 40-50%
shortening of the ICI was typically seen in the control group in
response to the 0.2% acetic acid irrigation (mean %
ICI=58.4%.+-.6.8%, n=8).
[0154] Inclusion of ketoprofen in the irrigation buffer leads to a
concentration-dependent inhibition of the shortening of the ICI
(FIG. 14). Complete inhibition was seen at approximately 3 .mu.M
ketoprofen and higher concentrations tended to go above 100% (data
not shown).
[0155] Inclusion of nifedipine in the irrigation buffer also leads
to a concentration-dependent inhibition of the shortening of the
ICI (FIG. 15). Complete inhibition was not seen but maximal effects
appeared to be at 1 .mu.M nifedipine, and higher concentrations
tended to plateau at approximately 75% of baseline.
Example VI
Pharmacokinetics of Absorption of a Nifedipine and Ketoprofen
Combination in a Rat Bladder Saline Model
[0156] The primary objective of this study was to measure systemic
plasma levels of ketoprofen and nifedipine during and after the
intravesical, local delivery of a combination of these drugs to
rats. A secondary objective of this study was to determine the rate
of appearance of ketoprofen and nifedipine when administered
individually or in combination. Finally, a third objective of this
study was to evaluate the effects of local drug delivery on the rat
bladder tissue content of the pro-inflammatory mediator, PGE.sub.2,
following surgical trauma to the bladder and subsequent
intravesical perfusion of each agent or the combination.
1. Methods
[0157] The study included three main treatment groups of animals: a
combination of both ketoprofen (10 .mu.M) and nifedipine (10
.mu.M); ketoprofen (10 .mu.M) alone; and nifedipine (10 .mu.M)
alone. A bladder catheter connected to an infusion pump was used to
deliver the drug solutions directly to the bladder at a constant,
defined rate.
[0158] For each of the three drug treatment groups, three distinct
bladder irrigation periods were employed that were defined by the
bladder perfusion solution for each period: 1) baseline (saline
only) for 1 hour; 2) drug in saline only for 1 hour; and 3)
post-drug saline period for 30 minutes (min). The animals were
anesthetized and the dome of the bladders were surgically implanted
with a catheter to allow perfusion of the test agents with an
infusion pump at a constant flow rate of 100 .mu.l/min. During
period 1, saline was the perfusion fluid used and no plasma samples
were collected. Starting at period 2, plasma samples were collected
at time points of 0, 15, 30, 45 and 60 min following perfusion of
test agents. Subsequent to 60 min of perfusion with test agents,
only saline was perfused for an additional 30 min and two
additional time points at t=75 and 90 min were collected to
determine the acute post-perfusion phase of test agents. Due to the
fixed concentrations of the irrigation solutions employed in the
study and the use of constant perfusion rates for fixed constant
times, a fixed, uniform dose of each agent was delivered to all
animals.
[0159] Whole blood samples were collected into K.sub.2 EDTA tubes
at the specified collection times. The volume of whole blood
collected was approximately 0.2 mL per sample. The blood was spun
in a centrifuge and the plasma transferred into polypropylene
tubes. Plasma samples were stored frozen at -80.degree. C. until
shipment for analysis. Rats were euthanized by CO.sub.2 inhalation
and the bladder was rapidly dissected and frozen in liquid nitrogen
and stored frozen at -80.degree. C. until assayed for tissue
PGE.sub.2 content.
[0160] The combination of ketoprofen and nifedipine was formulated
in accordance with an aspect of the invention to include ketoprofen
(10 mM), and nifedipine (10 mM) in a 60% polyethylene glycol 400
(PEG 400):40% water solvent base, including 50 mM sodium citrate
buffer for a pH 7.5 solution in a 5 mL glass vial. Immediately
prior to use, the combination solution was diluted in the standard
irrigation fluid at a ratio of 1:1000 such that the final
concentrations of the active drugs delivered directly to the
bladder were each 10 .mu.M. For these experiments, a fixed
concentration ratio of 1:1 nifedipine:ketoprofen was chosen, and
final concentrations of 10 .mu.M for each agent were maintained in
the irrigation buffer.
2. Results
[0161] The study demonstrated a very low level of systemic
absorption of ketoprofen following perfusion of the bladder with
saline containing 10 .mu.M ketoprofen for 60 min. In four out of
six rats, a narrow range of C.sub.max between 4.3-5.8 ng/ml was
seen at 60 min. At the 60 min time point, the perfusion with 10
.mu.M ketoprofen was stopped and normal saline irrigation was
continued for an additional 30 min period. For the group of four
out of six rats which showed peak plasma levels of about 5 ng/ml,
plasma levels decreased at 75 and 90 minutes following cessation of
ketoprofen perfusion. Delayed absorption during the 75-90 minute
interval was observed in the other two animals in the
ketoprofen-only group.
[0162] For comparison, the ketoprofen levels were also determined
for the combination of ketoprofen and nifedipine. The increase in
systemic plasma levels was approximately linear over time during
the initial 60 minute drug perfusion phase and the absolute mean
plasma levels of 9.3 ng/ml (n=6) at 60 minutes were well below the
acceptable therapeutic daily dose of ketoprofen. As in the case of
the ketoprofen only group, the perfusion with the combination was
stopped and normal saline irrigation was continued for an
additional 30 minute period. The mean ketoprofen values for all
animals (n=6) were not significantly different at 60, 75 and 90
minutes.
[0163] A comparison of the mean plasma ketoprofen results are
presented graphically in FIG. 16 for the ketoprofen-only group and
the combination group. The mean values (and standard error of the
means, SEMs) clearly show the constant plasma levels for the
combination after 60 minutes. Although small differences are
apparent in the earliest phase of the time-course, no significant
differences were observed either in the peak levels or in the
absorption kinetics for the ketoprofen plasma levels in the
combination group versus the ketoprofen alone group after 30
minutes, or in the peak levels, indicating that no apparent
ketoprofen-nifedipine drug interactions were present.
[0164] The overall kinetic profile observed for nifedipine was
similar to that observed for ketoprofen. In the nifedipine-only
plasma group, nifedipine plasma levels increased linearly in 5/6
animals and some delayed absorption was observed in only 1/6
animals. The C.sub.max plasma level in the nifedipine group was in
the range of 10.6-16.0 ng/ml at 60 minutes for 5/6 animals. The
mean peak plasma levels observed at 60 minutes were below the
acceptable mean peak levels of 79.+-.44 ng/ml that are obtained in
man as a result of an oral therapeutic daily dose of
nifedipine.
[0165] The increase in nifedipine systemic plasma levels from the
combination of ketoprofen and nifedipine also exhibited a linear
increase with increasing time for the initial 60 minute drug
perfusion period. The C.sub.max plasma levels in the combination
group had a mean value of 18.2 ng/ml and values ranged from
8.2-34.6 ng/ml at 60 minutes for all six animals. The mean peak
plasma levels observed at 60 minutes are about one fourth the mean
peak levels that are obtained as a result of oral therapeutic daily
dose of nifedipine.
[0166] As shown in FIG. 17, a comparison of the mean peak plasma
concentrations of nifedipine (and plotted SEMs) shows the similar
linear increase that occurs during the initial perfusion phase of
intravesical delivery. No significant differences in nifedipine
plasma levels were seen in the nifedipine only group when compared
with the nifedipine and ketoprofen combination drug product
group.
[0167] At the end of the 90 min bladder perfusion period, bladders
were harvested from the animals and subsequently the entire bladder
was analyzed for PGE.sub.2 content using an enzyme immunoassay
system. Data shown in FIG. 18 are expressed as the mean of
PGE.sub.2 using units of pg/mg protein.+-.the standard error of the
mean from six animals per treatment group. When animals were
treated with nifedipine, bladder tissue PGE.sub.2 levels of
421.+-.97 pg/mg protein (n=6) were observed compared to
statistically significantly (p<0.05) lower levels in the
presence of only ketoprofen or ketoprofen and nifedipine in the
combination treatment group, 83.+-.22 (n=6) and 115.+-.63 pg/mg
(n=5), respectively. No statistically significant differences were
seen between the ketoprofen treatment or the combination treatment
groups. In summary, ketoprofen treatment alone or treatment with
the combination during bladder perfusion significantly inhibited
PGE.sub.2 formed in the whole bladder relative to the nifedipine
treatment group.
3. Discussion
[0168] Using a method of intravesical perfusion for local drug
delivery, the drugs tested in this study were directly in contact
with the absorptive site within the bladder. The continuous
perfusion maintained constant drug concentrations of either
ketoprofen, nifedipine or the combination within the bladder during
the period of drug delivery. Under these conditions, minimal
systemic exposure to the drugs occurred in female rats during a 1
hour intravesical perfusion. Low levels of each drug were
detectable within the first 15 min interval measured, and
absorption progressed gradually as an approximately linear function
over time of drug perfusion for each agent.
[0169] The locally delivered drugs and drug combination were
exposed to the structures of the bladder, including the
uroepithelium, C-fiber afferents, efferents and smooth muscle. The
data obtained in the study show that this action is local and
cannot be ascribed to systemic effect that could be mediated
through central nervous system mechanisms because the initial
levels in the plasma for both drugs tested are so low.
[0170] Comparison of the plasma levels for each agent tested to
known human levels associated with normal oral dosing reveals the
magnitude of the difference observed. In the combination treatment
group, the maximal levels for ketoprofen were about 400-fold less
than the peak plasma levels (C.sub.max) in humans that are
associated with the acceptable therapeutic daily dose of ketoprofen
(rat mean ketoprofen plasma level of 9.29.+-.2.13 ng/ml at 60 min).
For comparison, the accepted daily mean peak C.sub.max for a single
200 mg ketoprofen tablet (a single oral dose) is 3900 ng/ml.
Similarly, peak levels observed for nifedipine were approximately
15 ng/ml to 25 ng/ml. The maximal levels (C.sub.max) typically
occurred at the end of 60 min drug perfusion period or within the
following 30 min sampling period. For comparison with known plasma
levels from conventional oral dosing, the accepted daily C.sub.max
for a single 10 mg immediate release nifedipine tablet is reported
to be 79.+-.44 ng/ml. Systemic exposure was comparable for
ketoprofen plasma levels whether administered alone or with
nifedipine. Similarly, nifedipine plasma levels were comparable
whether administered alone or with ketoprofen.
[0171] This study also determined the PGE.sub.2 content of the
bladder for each of the treatment conditions in the study. An
additional finding of significance is the long-lasting effect of
ketoprofen that was measured in the assay of whole bladder
PGE.sub.2 levels. The low concentrations of the ketoprofen
treatment alone or the combination treatment during bladder
perfusion significantly inhibited PGE.sub.2 formed in bladder
tissue relative to the nifedipine treatment group. The PGE.sub.2
bladder tissue levels in the presence of ketoprofen were not
significantly different from those following treatment with the
combination. Because delivery of the drug was stopped at 60 minutes
in this study, and then saline was used to irrigate for an
additional 30 minutes, this showed that PGE.sub.2 inhibition
remained active in the post-drug delivery period. Thus, ketoprofen
demonstrated an extended period of anti-inflammatory activity in
this model of local, intravesical drug delivery.
Example VII
[0172] The purpose of this study was to evaluate the solubility of
ketoprofen and nifedipine in aqueous liquid solution
formulations.
1. Methods
[0173] Three ketoprofen and nifedipine combo liquid formulations,
identified as F3/1, F10/3, and F30/10, were prepared according to
the composition shown in Table 8 below. In all three test
formulations, 50 mM sodium citrate aqueous buffer was used. The
target solubility of ketoprofen/nifidipine for F3/1, F10/3, and
F30/10 were 3 mM/1 mM, 10 mM/3 mM, and 30 mM/10 mM
respectively.
TABLE-US-00007 TABLE 8 Solubility Results for Three Nifedipine and
Ketoprofen Combination Formulations PEG400 % (v/v) Added
Approximate Formulation Formulation to Target Solubility Saturation
Solubility ID Buffer Buffer (Ketoprofen/Nifedipine)
(Ketoprofen/Nifedipine) F3/1 50 mM Na 35% 3 mM/1 mM 4.5 mM/1.5 mM
citrate buffer pH 5.5 F10/3 50 mM Na 50% 10 mM/3 mM 15 mM/4.5 mM
citrate buffer pH 5.5 F30/10 50 mM Na 60% 30 mM/10 mM 45 mM/15 mM
citrate buffer pH 5.5
2. Results
[0174] In order to achieve complete dissolution of both actives,
ketoprofen and nifedipine, in the formulations, different
percentages of PEG 400, 35% v/v PEG 400 (F3/1), 50% v/v PEG 400
(F10/3), 60% v/v PEG 400 (F30/10), were used as a cosolvent. With
the assistance of PEG 400 as a solubilizing agent, the approximate
saturation solubility of ketoprofen and nifedipine in all three
formulations was approximately 1.5x of their respective target
solubility. The solubility results in Table 8 clearly indicate that
PEG 400 is a suitable solubility enhancing agent for both drugs
when it is desired to prepare highly concentrated combination
solution formulations.
Example VIII
[0175] The purpose of this study was to evaluate the stability of
exemplary combination ketoprofen and nifedipine aqueous liquid
solution formulations.
1. Methods
[0176] Four exemplary ketoprofen and nifedipine combination
solution formulations, identified as F1 to F4, were prepared
according to the composition shown in Table 9. In all four
formulations, the concentrations of the active drugs were 3 mM for
Ketoprofen and 1 mM for Nifedipine. All four formulations employed
sodium citrate buffer (pH 5.5) with a 35% v/v of PEG 400. The ionic
strength of the buffer used was 50 mM for F1 and F2, and 20 mM for
F3 and F4. No antioxidant was added to the virgin formulation F1,
while 0.05% propyl gallate, 0.02% sodium metabisulfite, and 0.05%
propyl gallate plus 0.02% sodium metabisulfite were added to the
combination formulations F2, F3, and F4 respectively.
TABLE-US-00008 TABLE 9 Tested Nifedipine and Ketoprofen Combination
Formulations Drug Concentration Formulation (Ketoprofen/
Formulation Antioxidants ID Nifedipine) Vehicle Added F1 3 mM/1 mM
50 mM NaCitrate None (pH 5.5) w/ 35% v/v PEG 400 F2 3 mM/1 mM 50 mM
NaCitrate 0.05% Propyl (pH 5.5) w/ 35% gallate v/v PEG 400 F3 3
mM/1 mM 20 mM NaCitrate 0.02% Sodium (pH 5.5) w/ 35% metabisulfite
v/v PEG 400 F4 3 mM/1 mM 20 mM NaCitrate 0.05% Propyl (pH 5.5) w/
35% gallate v/v PEG 400 & 0.02% Sodium metabisulfite
[0177] An isocratic high performance liquid chromatograph (HPLC)
method was used to quantify ketoprofen and nifedipine and their
related substances in these test solution formulations after
storage for different periods of time. Formulation samples were
taken and diluted into mobile phase to obtain a final concentration
of approximately 0.76 mg/mL to 2.54 mg/mL for ketoprofen and
approximately 0.35 mg/mL to about 1.15 mg/mL for nifedipine.
Chromatographic conditions for the related substances assay were as
follows: (1) detection wave length: UV 241 nm; (2) column: Zorbax
SB-C18, 5 .mu.M, 4.6.times.150 mm; (3) column temperature:
30.+-.1.degree. C.; (4) flow rate: 1.0 mL/min; (5) injection
volume: 20 .mu.L; (6) run time: 27 minutes.
2. Results
[0178] FIG. 19 shows an example chromatogram of the combination
solution formulation F1 after stressing by storing at 60.degree. C.
for 1 month. The two active ingredients, ketoprofen and nifedipine,
have a retention time of 24.19 minutes and 19.31 minutes
respectively. There are four main related substances with relative
retention times (RRT) of 0.34, 0.58, 0.75, and 0.87 relative to the
nifedipine peak. This stability data is summarized in Table 10.
TABLE-US-00009 TABLE 10 Total related Substance (%) of Ketoprofen
and Nifedipine in Tested Formulations After Storage at Different
Temperatures Formulation ID Days 4.degree. C. 25.degree. C.
40.degree. C. 60.degree. C. F1 0 -- 1.08 -- -- 14 1.17 4.17 8.83 28
1.49 3.39 6.69 16.45 F2 0 -- 1.07 -- -- 14 1.57 -- 2.89 3.63 28
1.89 5.46 3.18 4.75 F3 0 -- 1.34 -- -- 14 1.76 2.86 4.54 8.39 28
2.11 3.51 5.44 12.68 F4 0 -- 0.28 -- -- 14 0.29 0.31 0.34 0.81 28
0.30 0.33 0.51 1.49
[0179] The stability data in Table 10 indicates that the chemical
stability of ketoprofen and nefidipine, especially nifedipine, is
significantly improved in the presence of a small amount of either
propyl gallate (0.05% w/v) or sodium metabisulfite (0.02% w/v) at
elevated temperatures such as 40.degree. C. and 60.degree. C., with
this effect being unexpectedly pronounced for propyl gallate. When
a small quantity of both propyl gallate (0.05% w/v) and sodium
metabisulfite (0.02% w/v) is added to F4, the stability of the two
drugs at all temperatures is significantly improved when compared
with the other three combination formulations without antioxidant
or with one of the two antioxidants alone, suggesting additive or
synergistic degradation inhibition effect of the two
antioxidants.
[0180] While the preferred embodiment of the invention has been
illustrated and described, it will be appreciated that various
changes to the disclosed solutions and methods can be made therein
without departing from the spirit and scope of the invention. It is
therefore intended that the scope of letters patent granted hereon
be limited only by the definitions of the appended claims.
* * * * *